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INTRODUCTION 
           Despite a major decline in incidence and mortality over several decades, 
stomach cancer is still the fourth most common cancer and the second most 
common cause of cancer death in the world. There is a 10-fold variation in 
incidence between populations at the highest and lowest risk. The incidence is 
particularly high in East Asia, Eastern Europe, and parts of Central and South 
America, and it is about twice as high among men than among women. 
Prognosis is generally rather poor, with 5-year relative survival below 30% in 
most countries.  
           The best established risk factors for stomach cancer are Helicobacter 
pylori infection, the by far strongest established risk factor for distal stomach 
cancer, and male sex, a family history of stomach cancer, and smoking . While 
some factors related to diet and food preservation, such as high intake of salt-
preserved foods and dietary nitrite or low intake of fruit and vegetables, are 
likely to increase the risk of stomach cancer, the quantitative impact of many 
dietary factors remains uncertain, partly due to limitations of exposure 
assessment and control for confounding factors.   
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REVIEW OF LITERATURE 
Epidemiology of Stomach Cancer 
  Gastric cancer remains one of the most common forms of cancer 
worldwide with approximately 870,000 new cases and 650,000 deaths per year 
[1,2] accounting for about 9.9 percent of new cancers [3].    
The worldwide incidence of gastric cancer has declined rapidly over the 
recent few decades. Part of the decline may be due to the recognition of certain 
risk factors such as H. pylori and other dietary and environmental risks. The 
decline first took place in countries with low gastric cancer incidence such as the 
United States, while the decline in countries with high incidence like Japan was 
slower.   
          Gastric cancer used to be the leading cause of cancer deaths in the world 
until the 1980s when it was overtaken by lung cancer [4]. According to data 
collected by the World Health Organization, the most common forms of cancer 
worldwide are lung (12.3 percent), breast (10.4 percent), and colorectal (9.4 
percent) while the top three causes of death from cancer are lung (17.8 percent), 
gastric (10.4 percent), and liver (8.8 percent).  
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An interesting hypothesis is that the popularization of refrigerators marks 
a pivotal point for the decline [5]. Refrigerators improved the storage of food, 
thereby reducing salt-based preservation of food and preventing bacterial and 
fungal contamination. Refrigeration also allowed for fresh food and vegetables 
to be more readily available, which may be a valuable source of antioxidants 
important for cancer prevention.  
           Race 
The rates of gastric cancer are higher in Asian and South American   
countries than in the United States. Japan, Chile, and Venezuela have developed 
a very rigorous early screening program that detects patients with early stage 
disease (ie, low tumor burden). These patients appear to do quite well. Some 
researchers suggest that this reflects a fundamental biologic difference in the 
disease as it manifests in Western countries. 
In the United States, Asian and Pacific Islander males and females have 
the highest incidence of stomach cancer, followed by black, Hispanic, white, 
American Indian, and Inuit populations. 
Sex 
           In the United States, gastric cancer affects slightly more men than women; 
the American Cancer Society estimated that in 2009, 12,820 new cases will 
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occur in men and 8,310 in women.[4 ]Worldwide, however, gastric cancer rates 
are about twice as high in men as in women.[1 ] 
Age 
          Most patients are elderly at diagnosis. The median age for gastric cancer 
in the United States is 70 years for males and 74 years for females. The gastric 
cancers that occur in younger patients may represent a more aggressive variant 
or may suggest a genetic predisposition to development of the disease.  It 
appears that higher geographic latitudes are associated with a higher gastric 
cancer risk. Global incidence of stomach cancer in men: the highest rates occur 
in Eastern Asia, South America and Eastern Europe. 
Migration studies — Migration, and in particular, international migration, can 
lead to a change in risk, as the immigrants, especially second and third 
generations, adopt the lifestyle and consequently the local disease patterns. The 
risk of gastric cancer changes slowly in populations moving from high to low 
risk communities. Studies of Japanese migrants to the Unites States have 
confirmed that early exposure to environmental rather than genetic factors have 
a greater influence on mortality and incidence rates[6,7]. In the subsequent 
generations born in the United States, the mortality rate declined towards the 
lower rate of United States whites.  
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Change in histology pattern —   It is more prevalent in high-risk areas and is 
likely linked to environmental factors. The diffuse type, or infiltrative type, is 
equally frequent in both sexes, is more common in younger age groups, and has 
a worse prognosis than the intestinal type. There has been a worldwide decline 
in the incidence of the intestinal type in recent few decades that parallels the 
overall decline in the incidence of gastric cancer. By contrast, the decline in the 
diffuse type has been more gradual.   
Despite the decline in gastric cancer overall, there has been an explosive 
increase in incidence of cancer of the gastric cardia[8-10]. The shift from distal to 
proximal stomach may in part be due to the decrease in the distal cancers.   
The proximal tumors share demographic and pathological features with 
Barrett's associated esophageal adenocarcinoma and are more likely to occur in 
men, which parallels the male predominance in the increasing incidence of 
carcinoma in the lower third of the esophagus. The proximal tumors also differ 
from distal tumors in that they are not associated with a severe form of gastritis 
characterized by atrophy and/or intestinal metaplasia. Furthermore, they tend to 
be more aggressive than those arising from distal sites. Environmental factors or 
chemical carcinogens (eg, cigarette and alcohol) may be more strongly 
associated with cardiac carcinomas compared with more distal carcinomas [11].   
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Epidemiology of Gastric cancer in India 
In India, across the various registries, there is a wide variation in the 
incidence of gastric carcinoma. The incidence rate of gastric cancer is four times 
higher in Southern India compared with Northern India. Among the six 
registries, the highest incidence in both sexes is reported from Chennai and the 
lowest from Barshi. The incidence varies among different religious groups also. 
In Kashmir, Muslims have a higher incidence compared with Hindus, whereas 
the reverse trend is seen in Mumbai[12]. 
Site of lesion of cancer stomach in India 
 Worldwide, the incidence of proximal gastric carcinoma is on the 
increase. In India also a trend towards an increase in the incidence of cardia 
tumors is seen. This is evident in the data from Mumbai, where the percentage of 
cardia and fundus tumors increased from 13% in 1941–1968 to 23% in 1987–
1993 [13]. Nearly 95% of the tumors are adenocarcinomas. These may be further 
distinguished as intestinal and diffuse types. Intestinal type is seen more 
commonly than diffuse type in India.   In India more than 90% of all gastric 
cancers are diagnosed in an advanced stage, and in those subjected to surgery 
more than 70% have serosal infiltration [13]. 
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ANATOMY 
The stomach is roughly J-shaped, although its size and shape vary 
considerably.   The stomach has two surfaces—the anterior and posterior; two 
curvatures — the greater and lesser; and two orifices — the cardia and pylorus.  
 
               The stomach projects to the left, above the level of the cardia, to form 
the dome-like gastric fundus. Between the cardia and the pylorus lies the body of 
the stomach leading to a narrow portion, immediately preceding the pylorus, 
which is termed the pyloric antrum. The junction of the body with the pyloric 
antrum is marked by a distinct notch on the lesser curvature termed the incisura 
angularis. The junction of pylorus with duodenum is marked by a constriction 
externally and also by a constant vein (of Mayo)  which crosses it at this level. 
The thickened pyloric sphincter is easily felt and surrounds the lumen of the 
pyloric canal. The pyloric sphincter is an anatomical structure as well as a 
physiological mechanism.    
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Relations of the stomach 
•Anteriorly — the abdominal wall, the left costal margin, the diaphragm  and 
the left lobe of the liver. 
•Posteriorly—the lesser sac, which separates the stomach from the pancreas,  
transverse mesocolon, left kidney, left suprarenal, the spleen and the splenic 
artery. 
•Superiorly—the left dome of the diaphragm. The lesser omentum is attached 
along the lesser curvature of the stomach, the greater omentum along the greater 
curvature. These omenta contain the vascular and lymphatic supply of the 
stomach. 
 
 
 Relations of the stomach 
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The blood supply to the stomach  
 
The arterial supply of the stomach. 
•The left gastric artery—from the coeliac axis; 
•The right gastric artery—from the hepatic artery; 
 •The right gastro-epiploic artery—from the gastroduodenal branch of the 
hepatic artery; 
•The left gastro-epiploic artery—from the splenic artery; 
•The short gastric arteries—from the splenic artery. 
The corresponding veins drain into the portal system. 
The lymphatic drainage of the stomach accompanies its blood vessels. 
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Drainage zones of the stomach 
•Area I—the superior two-thirds of the stomach drain along the left and right 
gastric vessels to the aortic nodes. 
•Area II—the right two-thirds of the inferior one-third of the stomach  
•Area III — the left one-third of the greater curvature of the stomach drains 
along the short gastric and splenic vessels lying in the gastrosplenic and 
lienorenal ligaments, then, via the suprapancreatic nodes, to the aortic group. 
 
The lymph drainage of the stomach & three drainage zones. 
The lymph drainage of the stomach 
•Area I drains along the right and left gastric vessels to the aortic nodes. 
•Area II drains to the subpyloric and thence aortic nodes via lymphatics along 
the right gastro-epiploic vessels. 
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•Area III drains via lymphatics along the splenic vessels to the suprapancreatic 
nodes and thence to aortic nodes. drain along the right gastro-epiploic vessels to 
the subpyloric nodes and thence to the aortic nodes[14]. 
This extensive lymphatic drainage and the technical impossibility of its 
complete removal is one of the serious problems in dealing with stomach cancer. 
Involvement of the nodes along the splenic vessels can be dealt with by 
removing spleen, gastrosplenic and lienorenal ligaments and the body and tail of 
the pancreas. Lymph nodes among the gastro-epiploic vessels are removed by 
excising the greater omentum. However, involvement of the nodes around the 
aorta and the head of the pancreas may render the growth incurable. 
  
Risk factors for gastric cancer 
PRECURSOR LESIONS  
Atrophic gastritis — Atrophic gastritis is characterized by progressive atrophy 
of the glandular epithelium with loss of parietal and chief cells. The loss of the 
normal exocrine glands of the gastric mucosa causes hypochlorhydria and a 
resultant increase in gastric pH. An abnormally high pH in the stomach permits 
microbial colonization, some of which possess nitrate reductase, allowing 
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nitrosation that is genotoxic. In addition, there is a loss of endocrine cells, which 
normally secrete epidermal and transforming growth factors, thereby aiding the 
stomach in regenerating damaged tissue. Populations with a high prevalence of 
atrophic gastritis have a high prevalence of gastric cancer, and vice-versa [15].   
Intestinal metaplasia — Metaplasia is a potentially reversible change from a 
fully differentiated cell type to another cell type, a process in adaptation to 
environmental stimuli. The most common form of metaplasia in the stomach is 
the intestinal type. It occurs as a result of Helicobacter pylori infection, bile 
reflux, or can be induced experimentally by irradiation [16]. Intestinal metaplasia 
is more frequent in countries with a higher incidence of gastric carcinoma [17], 
and precedes gastric carcinoma [18].    
Dysplasia — Most patients diagnosed with high-grade dysplasia of the gastric 
mucosa either already have or soon develop gastric cancer. In gastrectomy 
specimens for gastric cancer, 20 to 40 percent of patients had associated 
dysplasia [19]. Progression of dysplasia to gastric cancer has been estimated at 21 
percent, 33 percent, and 57 percent of cases of mild, moderate, and severe 
dysplasia, respectively [20]. Epidemiological studies have shown that intestinal 
metaplasia and dysplasia in the stomach have a high cancer risk with high and 
low cancer risk [19]. The prevalence of intestinal metaplasia and dysplasia was 
much higher in areas with high risk for gastric cancer.                       
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              A widely accepted model of gastric cancer describes a progression from 
chronic gastritis to chronic atrophic gastritis, to intestinal metaplasia, dysplasia, 
and eventually to adenocarcinoma.   
              Similarly, gastric resection results in hypo- or achlorhydria, secondary 
hypergastrinemia, and bile reflux, especially after a Billroth II anastomosis.               
The increase in gastric pH would permit colonization of bacteria capable of 
converting dietary nitrates to potent mutagenic N-nitroso compounds. Chronic 
inflammation also results in epithelial cell damage with increased free radical 
generation, a further reduction in luminal ascorbic acid levels, and increased cell 
turnover.  
              This triad of events increased cell proliferation due to the promotional 
effects of hypergastrinemia and/or bile reflux, increased luminal levels of 
mutagens (eg, N-nitroso compounds and free radicals), and decreased luminal 
levels of protective factors (eg, vitamin C) provide an ideal milieu for enhanced 
carcinogenesis in susceptible hosts. The role of specific genetic alterations in 
this model remains unknown.  
Environmental risk factors — Emigrants from high-incidence to low-
incidence countries often experience a decreased risk of developing gastric 
carcinoma. Such findings strongly suggest that environmental factors have an 
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important role in the etiology of gastric cancer and that exposure to risk factors 
occurs early in life.  
Diet — Large epidemiologic studies demonstrating the association between diet 
and gastric cancer were based mainly upon the amount of food imported and 
produced rather than the actual food consumption [21]. This takes no account of 
the losses during storage, distribution, and consumption of food or any ethnic 
dietary differences. Nevertheless, the information provides important insight into 
environmental causes of gastric cancer.  
Nitroso compounds —One of the most consistent associations has been with 
dietary exposure to N-nitroso compounds[22]. N-nitroso compounds are 
generated after consumption of nitrates, which are natural components of foods 
like vegetables and potatoes and are used as a food additive in some cheeses and 
cured meats. Dietary nitrates are absorbed in the stomach and secreted in saliva 
in a concentrated form where they are reduced to nitrites by oral bacteria. 
Nitrites can react with nitrosatable compounds like amines, amides, and amino 
acids to form N-nitroso compounds. An increase in gastric nitrite has observed 
in patients with intestinal metaplasia, dysplasia, and gastric cancer. 
The uses of nitrate-based fertilizers [23] and pickled foods that contain 
nitrosated products correlates with gastric cancer . Diets low in vegetables, 
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fruits, milk, and vitamin A and high in fried food, processed meat, and fish and 
alcohol have been associated with an increased risk of gastric carcinoma in 
several epidemiologic studies [24]. 
Diets low in citrus fruit show the strongest association with gastric 
carcinoma [25]. The protection afforded by vegetables and fruits is most likely 
related to their vitamin C content, which is thought to reduce the formation of 
carcinogenic N-nitroso compounds inside the stomach. Cooked vegetables do 
not show the same protective effect as uncooked vegetables. 
Salt — High salt intake damages stomach mucosa and increases the 
susceptibility to carcinogenesis in rodents [26]. The risk of high salt intake was 
strongest in patients who had both H. pylori infection and atrophic gastritis [27].  
Folate — A meta-analysis of epidemiology studies found an inconsistent 
association between dietary folate and the risk of gastric cancer [28].  
Smoking — Several studies have examined the relationship between tobacco 
smoking and gastric cancer. A meta-analysis of 40 studies estimated that the risk 
was increased by approximately 1.5 to 1.60-fold and was higher in men[29]. A 
subsequent prospective study from Europe found a similar magnitude of risk, 
which diminished after 10 years of smoking cessation[30]. Approximately 18 
percent of gastric cancer cases were attributed to smoking.  
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Alcohol — A consistent association between alcohol consumption and the risk 
of gastric cancer has not been demonstrated. A study from Europe suggested that 
daily intake of wine may be protective [31].  
Socioeconomic status —The risk of distal gastric cancer is increased by 
approximately twofold in populations with low socioeconomic status[32]. By 
contrast, proximal gastric cancers have been associated with higher 
socioeconomic class [33].  
Gastric surgery — There is an increased risk of gastric cancer after gastric 
surgery, with the risk being greatest 15 to 20 years after surgery and then 
increasing with time [34]. The Billroth II procedure (gastrojejunostomy) carries a 
higher risk than the Billroth I (gastroduodenostomy). Although the exact cause 
of the increased risk is unknown, it is thought to be due to regurgitation of 
alkaline bile and pancreatic juice.    
Epstein-Barr virus — The Epstein-Barr virus (EBV) is associated with a 
number of malignancies, especially nasopharyngeal carcinoma. A possible role 
in gastric cancer was suggested in a study from Korea in which evidence of EBV 
was found in the tumor cells of 12 of 89 (13.5 percent) gastric carcinoma 
patients compared to none of 27 controls with a benign ulcer or any of the 
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benign tissues from the cases [35]. Some of the tumor cells had a histologic 
appearance similar to nasopharyngeal carcinoma.  
Since then, it has been estimated that between 5 and 10 percent of gastric 
cancers worldwide are associated with EBV [36]. EBV-associated gastric cancers 
are characterized by DNA methylation of the promoter region of various cancer-
associated genes, which silences the expression of these genes.   
EBV-associated gastric cancers have distinct clinicopathologic 
characteristics, including male predominance, preferential location in the gastric 
cardia, a diffuse type of histology, and perhaps a more favorable prognosis.  
Helicobacter pylori — The World Health Organization's International Agency 
for Research on Cancer classified Helicobacter pylori as a Group 1 or definite 
carcinogen [37]. As noted above, gastric carcinoma is believed to evolve as a 
progression from atrophy to metaplasia, dysplasia and then carcinoma. The most 
common cause of gastritis is Helicobacter pylori.  
Three sources of evidence support the association of H. pylori infection 
and gastric cancer: epidemiologic studies comparing gastric cancer and H. pylori 
infection prevalence rates, cross-sectional studies evaluating H. pylori infection 
in cancer patients, and prospective studies associating H. pylori with gastric 
cancer. Histologic association of the bacteria with tumor can be difficult to 
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determine because H pylori has an affinity for normal gastric mucosa but not 
metaplastic, dysplastic, or malignant tissue [38].   
Helicobacter pylori infection may trigger inflammation at the corpus 
mucosa that results in atrophy and intestinal metaplasia. H. pylori infection has 
been associated with an approximate 6-fold increase in the risk with 
adenocarcinomas distal to the cardia, including both intestinal and diffuse types.   
A paradox in H. pylori infection is that divergent clinical outcomes occur: 
patients may develop duodenal ulcer or gastric cancer, while the majority 
develop no significant clinical symptoms. Bacterial virulence factors alone have 
not adequately explained why the ulcer or the gastric cancer phenotype 
develops.    
HOST-RELATED FACTORS  
Blood group —   Individuals of blood group A have been known for decades to 
show an approximately 20 percent excess of gastric cancer than those of group 
O, B, or AB [40]. They also show a similar increase in the rate of pernicious 
anaemia. Some data suggest that group A may be particularly associated with the 
diffuse type of gastric cancer [39]. It is possible that the observed associations are 
not due to the blood group antigens themselves, but to the effects of genes 
closely associated with them.  
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Familial predisposition — A genetic predisposition to gastric cancer has been 
repeatedly confirmed [41].  A genetic predisposition for chronic atrophic gastritis, 
a precursor of gastric carcinoma, has been described and may account for at least 
some cases of familial gastric cancer [42].  Gastric cancer has been described in 
association with certain cancer syndromes (including hereditary nonpolyposis 
colorectal cancer, familial adenomatous polyposis, and Peutz Jeghers syndrome).  
A germline mutation within the E-cadherin gene (CDH1) was identified in 
a New Zealand family with diffuse gastric cancer[43] and in a European family in 
1998 [44].  Germ-line truncating mutations of the E-cadherin gene are detected in 
50 percent of diffuse-type gastric cancers [45].   
The disorder has an autosomal dominant pattern of inheritance. The 
lifetime cumulative risk for advanced gastric cancer has been estimated to be 67 
percent in men and 83 percent in women. Affected patients generally develop 
gastric cancer at an average age of 38 years.    
Genetic polymorphisms — The human interleukin 1 beta (IL-1B) gene is the 
most important candidate gene in the host that could affect the clinical outcome 
of H. pylori infection because it is upregulated by infection, is profoundly 
proinflammatory, and is the most powerful acid inhibitor known   
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Gastric polyps — Gastric polyps are present in less than 1% of the general 
population.[48]  Up to 90% of these lesions are hyperplastic polyps, which usually 
remain small, rarely exceeding 1.5 cm. The rate of malignant transformation is 
generally quite low (<1%) and confined to polyps larger than 1 cm.[49] The rare 
hyperplastic polyps that do undergo malignant transformation often form well 
differentiated intestinal-type cancer. Less common are adenomas in the stomach, 
which constitute less than 10% of gastric polyps. However, gastric adenomas 
undergo malignant transformation at a high rate.  Gastric  adenomas  can progress 
to dysplasia and then carcinoma in situ, which develops within 4 years of follow-
up in approximately 11% of cases[50].    
Hypertrophicgastropathy and immunodeficiencysyndromes — Hypertrophic 
gastropathy (including Menetrier's disease) and various immunodeficiency 
syndromes  have been linked with gastric cancer. However, the strength of these 
associations remains undefined.   
Gastric ulcer — Despite the known associations between H. pylori infection 
and peptic ulcer disease and H. pylori infection and gastric cancer, the 
association between benign gastric ulcer disease and gastric cancer remains 
controversial [46].  The risk of gastric cancer was increased among patients with 
benign gastric ulcers (incidence ratio 1.8), unchanged among patients with 
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prepyloric ulcers, and decreased among those with benign duodenal ulcers 
(incidence ratio 0.6).  
Pernicious anemia — Pernicious anemia, a sequela of autoimmune chronic 
atrophic gastritis directed against hydrogen-potassium ATPase in the gastric 
parietal cells, is associated with an increased risk of intestinal-type gastric 
cancer. A two- to threefold excess risk has been reported [47] but, as with other 
predisposing conditions, the actual degree of risk varies with the duration of 
disease and geographic location.    
Pathology of gastric cancer 
          Early  gastric cancer 
Early gastric cancers, defined as tumors confined to the mucosa or 
submucosa  regardless of lymph node status.  
Classification of early gastric cancer 
Type I - lesions protrude into the lumen and appear on endoscopy as a polyp on 
a short, broad-based stalk with an elevation greater than 5 mm. These 
protrusions are occasionally multiple but remain localized. They may be 
confused with thickened mucosal folds.  
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 Type II - lesions are superficial with an uneven surface. These changes are 
subtler than type I lesions, and multiple biopsies are necessary for suspected 
lesions. Three subtypes are described:  
      A. Type IIa has a slightly elevated surface of less than 5 mm   
      B. Type IIb is characterized by a surface that is flat but irregular with no 
distinct elevations or depressions. 
      C. Type IIc is a localized area of depression of less than 1.5 cm in area 
without penetration of the muscularis mucosa.  
Type III - is a localized shallow excavation or ulceration in the gastric lining.  
Types II and III account over 60 percent of early gastric cancers. 
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Advanced gastric cancer   
Advanced  cancers commonly present as polypoid or fungating masses 
with superficial ulceration. Superficial spreading or infiltrating (linitis plastica) 
forms are less frequently seen.  
Histology — The vast majority of malignant neoplasms of the stomach are 
adenocarcinomas.   
Classifications of  Advanced gastric cancer   
 
 
The intestinal or expanding type The diffuse or infiltrative type 
Resembles colorectal cancer and is characterized by 
distinct glands comprised of well differentiated 
columnar epithelial cells with a well developed brush 
border. 
Characterized by poorly organized clusters   or solitary 
mucin-rich (signet ring) cells and a diffusely infiltrating 
growth pattern. 
Predominate in high-risk populations Predominates in women 
Is more common in men and older patients Younger patients 
Is associated with a better prognosis Carries a poorer prognosis 
Is often preceded by a prolonged precancerous state. Is not preceded by a known precancerous lesion. 
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 Lauren's classification system 
 intestinal   
 diffuse types [51]  
 Ming's classification system  
 expanding and  
 infiltrating types[52].  
CLINICAL FEATURES AND DIAGNOSIS OF GASTRIC CANCER 
Clinical features — Weight loss and persistent abdominal pain are the most 
common symptoms at initial diagnosis [53].  
Presenting symptoms of gastric cancer are 
Symptom   Percent  
Weight loss  62  
Abdominal pain   52  
Nausea   34  
Dysphagia   26  
Melena  20  
Early satiety  18  
Ulcer-type pain  17  
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Weight loss usually results from insufficient caloric intake rather than 
increased catabolism, and may be attributable to anorexia, nausea, abdominal 
pain, early satiety, and/or dysphagia.  
The abdominal pain tends to be epigastric, vague and mild early in the 
disease, but more severe and constant as the disease progresses.  
Dysphagia is a common presenting symptom in patients with cancers 
arising in the proximal stomach  or at the esophagogastric junction.  
Patients may also present with nausea or early satiety from the tumor 
mass, or in cases of an aggressive form of diffuse-type gastric cancer called 
linitis plastica, from poor distensibility of the stomach. They may also present 
with a gastric outlet obstruction from an advanced distal tumor.  
Occult gastrointestinal bleeding with or without iron deficiency anemia is 
not uncommon, while overt bleeding (ie, melena or hematemesis) is seen in less 
than 20 percent of cases. The presence of a palpable abdominal mass is the most 
common physical finding and generally indicates long-standing, advanced 
disease [53].  
Approximately 25 percent of patients have a history of gastric ulcer. All 
gastric ulcers should be followed to complete healing, and those that do not heal 
should undergo resection [53].   
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Signs of tumor extension  
             More unusual presentations, related to the propensity of gastric cancer to 
spread by direct extension through the gastric wall, can also alert the clinician to 
the diagnosis.  
Signs of  spread via lymphatics 
 Virchow's node 
 Since gastric cancer can spread via lymphatics, the physical 
examination may reveal a left supraclavicular adenopathy which is 
the most common physical examination finding of metastatic 
disease,  
 Sister Mary Joseph's node  
 A  periumbilical nodule    
 Irish node  
 A left axillary node. 
Signs of  Peritoneal spread 
 Krukenberg's tumor 
 Peritoneal spread can present with an enlarged ovary   
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 Blumer's shelf  
 a mass in the cul-de-sac on rectal examination. 
 Ascites  
 can be the first indication of peritoneal carcinomatosis.  
A palpable liver mass can indicate metastases, although metastatic disease 
to the liver is often multifocal or diffuse.   
Paraneoplastic manifestations —   
 Dermatologic manifestations 
 sign of Leser-Trelat - the sudden appearance of diffuse seborrheic 
keratoses   
 acanthosis nigricans-  characterized by velvety and darkly pigmented 
patches on skin folds. 
 Neither finding is specific for gastric cancer.  
Other paraneoplastic manifestations   
 Microangiopathic hemolytic anemia  
 Membranous nephropathy 
 Hypercoagulable states (Trousseau's syndrome).  
28 
 
 Polyarteritis nodosa has been reported as the single manifestation of 
an early and surgically curable gastric cancer.    
DIAGNOSIS  
Endoscopy — Tissue diagnosis and anatomic localization of the primary tumor 
are best obtained by upper gastrointestinal endoscopy.  Upper  endoscopy is also 
more sensitive and specific for diagnosing a variety of gastric, esophageal and 
duodenal lesions than alternative diagnostic strategies . The early use of upper 
endoscopy in patients presenting with gastrointestinal complaints may be 
associated with a higher rate of detection of early gastric cancers.   
Endoscopic techniques — During endoscopy, any suspicious-appearing gastric 
ulceration should be biopsied. A single biopsy has a 70 percent sensitivity for 
diagnosing an existing gastric cancer, while performing seven biopsies from the 
ulcer margin and base increases the sensitivity to greater than 98 percent [54].   
The diagnosis of a particularly aggressive form of diffuse-type gastric 
cancer, so called "linitis plastica," can be difficult endoscopically. Because these 
tumors tend to infiltrate the submucosa, superficial mucosal biopsies may be 
falsely negative. For this reason, the combination of strip and bite biopsy 
techniques should be used when there is a suspicion of a diffuse type of gastric 
cancer [55].   
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 Barium studies — Barium studies can identify both malignant gastric ulcers 
and infiltrating lesions. However, false-negative barium studies can occur in as 
many as 50 percent of cases [56].   
Thus, in most settings, upper endoscopy is the preferred initial diagnostic 
test for patients in whom gastric cancer is suspected. The one scenario in which 
a barium study may be superior to upper endoscopy is in patients with linitis 
plastica. The decreased distensibility of the stiff, "leather-flask" appearing 
stomach is more obvious on the radiographic study, and the endoscopic 
appearance may be relatively normal.  
STAGING AND PREOPERATIVE EVALUATION  
Staging systems — There are two major classification systems currently in use 
for gastric cancer. The most elaborate, the Japanese classification, is based upon 
refined anatomic location, particularly of the lymph node stations [57]. The other 
staging system, developed jointly by the American Joint Committee on Cancer 
(AJCC) and the International Union Against Cancer (UICC) is the classification 
most often used in the Western hemisphere, and increasingly, in Asian countries 
as well.  
TNM staging criteria — The staging schema of the AJCC/UICC is based on 
tumor (T), node (N), and metastasis (M) classifications[58]. 
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American Joint Committee on Cancer staging for gastric cancer 
Tumor (T) stage  
TX  Primary tumor cannot be assessed  
 
T0  No evidence of primary tumor  
 
T1s Carcinoma in situ: intra-epithelial tumor without invasion of the lamina propia  
 
T1 Tumor invades lamina propria or submucosa  
 
T2 Tumor invades muscularis propria or subserosa  
 
      T2a Tumor invades muscularis propria 
      T2b Tumor invades subserosa 
T3 Tumor penetrates serosa (visceral peritoneum) without invasion of adjacent structures*  
 
T4 Tumor invades adjacent structures* 
Nodal (N) stage  
NX Regional lymph node(s) cannot be assessed  
N0 No regional lymph node metastasis   
N1 Metastasis in 1 to 6 regional lymph nodes   
N2 Metastasis in 7 to 15 regional lymph nodes 
N3 Metastasis in more than 15 regional lymph nodes  
Metastasis (M) stage  
Mx Presence of distant metastasis cannot be assessed  
M0 No distant metastasis  
M1 Distant metastasis  
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Stage grouping  
 Stage 0    Tis N0 M0    
 Stage 1A   T1 N0 M0   
 Stage 1B     T1 N1 M0 T2a/b N0 M0   
Stage II T1 N2 M0  T2a/b N1 M0 T3 N0 M0  
Stage IIIA T2a/b N2 M0 T3 N1 M0  T4 N0 M0  
 
Stage IIIB     T3 N2 M0    
Stage IV   T1-3 N3 M0 T4 N1-3 M0  
 
 T stage is dependent on depth of tumor invasion and not size. 
 Nodal stage is based upon the number of positive lymph nodes.  
 Patients who have no obvious visceral metastases but who have 16 or 
more pathologically involved nodes are classified as having stage IV disease, 
which accurately reflects the poor prognosis for these patients.  
The validity of the AJCC stage groupings is well established. Five-year 
survival rates range from 78 percent for patients with superficial T1 tumors and 
negative lymph nodes (stage IA disease) to 7 to 8 percent for patients with N3 
nodes or any distant metastases [59].   
Clinical staging and the selection of treatment — Although staging is 
most accurately determined through surgical pathology, clinical staging directs 
the initial approach to therapy: Patients who appear to have locoregional disease 
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(stage I to III) after preoperative testing are potentially curable and should be 
referred for multidisciplinary evaluation to identify the best treatment strategy. 
Patients who have T1 to T3, N1 or N2 tumors considered operable and 
resectable could be referred for initial surgery. However, neoadjuvant therapy, 
particularly on a clinical trial, is also a reasonable approach. Patients with 
advanced stage IV disease are usually referred for palliative therapy depending 
on their symptoms and functional status. Multiple studies indicate both longer 
survival and better quality of life with systemic treatment.   
Abdominopelvic CT scan — Dynamic computerized tomography (CT) scan 
imaging is usually performed early in the preoperative evaluation after a 
diagnosis of gastric cancer is made. CT is widely available and noninvasive. It is 
best suited to evaluating widely metastatic disease, especially hepatic or adnexal 
metastases, ascites, or distant nodal spread. Patients who have CT-defined 
visceral metastatic disease can avoid unnecessary surgery, although biopsy 
confirmation is recommended because of the risk of false-positive findings.  
Peritoneal metastases and hematogenous metastases smaller than 5 mm 
are frequently missed by CT, even using advanced techniques. In 20 to 30 
percent of patients with a negative CT, intraperitoneal disease will be found at 
either staging laparoscopy or at open exploration.  
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A disadvantage of CT is its limited accuracy for assessing the depth of 
primary tumor invasion (particularly with small tumors) and the presence of 
lymph node involvement. CT accurately assesses the T stage of the primary 
tumor in only about 50 to 70 percent of cases [31]. Disease is more often 
understaged because the depth of invasion is underestimated; however, 
overstaging also occurs.  
The accuracy of CT for determining regional lymph node involvement is 
also marginal. The classification of nodal status is usually based on lymph node 
size, and sensitivity is limited for involved nodes that are smaller than 0.8cm. 
Furthermore, false-positive findings may be attributed to inflammatory 
lymphadenopathy. Sensitivity and specificity rates for detection of regional 
nodal metastases are ranging from 65 to 97 [60].  
Endoscopic ultrasonography — Endoscopic ultrasonography (EUS) is thought 
to be the most reliable nonsurgical method available for evaluating the depth of 
invasion of primary gastric cancers, particularly for early (T1) lesions[61]. The 
accuracy of EUS for differentiation of individual tumor stages (T1 to T4) ranges 
from 77 to 93 percent[62], with the experience of the operator markedly 
influencing these rates.  
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EUS-guided fine needle aspiration of suspicious nodes and regional areas 
adds to the accuracy of nodal staging [64]. Over staging can also occur that is 
attributed to inflammation around the tumor or in lymph nodes[63]. 
Distinguishing T2 from T3 lesions  is especially difficult because of this 
problem. 
EUS is not recommended for pretreatment evaluation of gastric cancer in 
guidelines from the National Comprehensive Cancer Network (NCCN) [65].  
EUS staging is perhaps of greatest utility for patients with early gastric 
cancer because accurate assessment of submucosal invasion is essential before 
considering the option of endoscopic mucosal resection.   
PET scan — The role of positron emission tomography (PET) using 18-
fluorodeoxyglucose (FDG) in the preoperative staging of gastric 
adenocarcinoma is evolving. From the standpoint of locoregional staging, 
integrated PET/CT imaging can be useful to confirm malignant involvement of 
CT-detected lymphadenopathy[66]. However, this usually does not impact the 
decision to proceed to surgery. Furthermore, a negative PET is not helpful since 
even large tumors with a diameter of several centimeters can be falsely negative 
if the tumor cells have a fairly low metabolic activity. This scenario is fairly 
common in gastric cancer, particularly the diffuse type [67,68].  
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The main benefit of PET is that it is more sensitive than CT for the 
detection of distant metastases [68]. An important caveat is that the sensitivity of 
PET scanning for peritoneal carcinomatosis is only approximately 50 percent 
[69]
. Thus, PET is not an adequate replacement for staging laparoscopy.  
NCCN guidelines for preoperative evaluation of gastric cancer suggest 
integrated PET/CT [65].   
Chest imaging — A preoperative chest x-ray is recommended in patients with 
gastric cancer [65]. However, the sensitivity for metastases is limited, and a chest 
CT scan is preferred (particularly for patients with a proximal gastric cancer) if 
the detection of intrathoracic disease would alter the treatment plan.  
Serologic markers — Serum levels of carcinoembryonic antigen (CEA), the 
glycoprotein CA 125 antigen (CA 125), CA 19 9, and CA 72 4 may be elevated 
in patients with gastric cancer [70]. However, low rates of sensitivity and 
specificity prevent the use of any of these serologic markers as diagnostic tests 
for gastric cancer.        
Recommendations for preoperative evaluation and staging of gastric 
cancer from the NCCN do not include assay of any tumor marker [68].  
Staging laparoscopy — Laparoscopy, while more invasive than CT or EUS, 
has the advantage of directly visualizing the liver surface, the peritoneum, and 
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local lymph nodes. Between 20 and 30 percent of patients who have disease that 
is beyond T1 stage on EUS will be found to have peritoneal metastases despite 
having a negative CT scan [71]. As noted previously, the sensitivity of PET scans 
for the detection of peritoneal carcinomatosis is only about 50 percent.   
Another advantage to laparoscopy is the opportunity to perform peritoneal 
cytology in patients who have no visible evidence of peritoneal spread. In most 
series this is a poor prognostic sign, even in the absence of overt peritoneal 
dissemination, and predicts for early peritoneal relapse. The majority of patients 
who are found to have peritoneal disease on laparoscopy will never require a 
laparotomy or resection.  
Preoperative staging laparoscopy is advisable in any medically fit patient 
who appears to have more than a T1 lesion on EUS, no histologic confirmation 
of stage IV disease, and who would not otherwise require a palliative 
gastrectomy because of symptoms. Diagnostic laparoscopy should also be 
undertaken in patients who are being considered for neoadjuvant therapy trials.    
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MANAGEMENT OF GASTRIC CANCER 
Surgical treatment for localized disease — Complete surgical eradication of a 
gastric tumor with resection of adjacent lymph nodes, represents the best chance 
for long-term survival. Since resection of the primary lesion also offers the most 
effective means of symptom palliation, abdominal exploration with curative 
intent should be undertaken unless there is unequivocal evidence of 
disseminated disease, a neoadjuvant approach is considered, or there are other 
contraindications to surgery.  
The choice of operation for gastric cancer depends upon the location of 
the tumor within the stomach, the clinical stage, and the histologic type.  
The major surgical considerations include the extent of luminal resection 
(total versus subtotal gastrectomy) and the extent of lymph node dissection.  
Total versus subtotal gastrectomy — Gastrectomy is the most widely used 
approach for therapy of invasive gastric cancer.  Total gastrectomy   is usually 
performed for lesions in the proximal (upper third) of the stomach, while distal 
subtotal gastrectomy with resection of adjacent lymph nodes appears to be 
sufficient for lesions in the distal (lower two-thirds) of the stomach. However, 
patients with large midgastric lesions, or infiltrative disease (eg, linitis plastica) 
may require total gastrectomy.    
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Distal tumors — At least two trials show no added survival benefit for total 
compared to subtotal gastrectomy for patients with distal tumors [72,73].   The 
overall complication and perioperative mortality rates were 32 and 1.3 percent, 
respectively with total gastrectomy, and 34 and 3.2 percent with subtotal 
gastrectomy, respectively. Five-year survival was similar in both groups.  
Proximal and GE junction tumors —   Tumors of the proximal stomach that 
do not invade the GE junction can be approached by either a total gastrectomy.   
The Roux-en-Y reconstruction performed during total gastrectomy is associated 
with an extremely low incidence of reflux esophagitis compared to the roughly 
one-third of patients who develop reflux esophagitis after a proximal subtotal 
gastrectomy [74]. Proximal subtotal may fail to fully remove the lymph nodes 
along the lesser curvature. Thus, the most common site of nodal metastases may 
not be fully treated surgically.  
Siewert classification of GE junction tumors [75] 
 Type I — Carcinoma associated with Barrett's esophagus or true 
esophageal carcinoma  growing down to the GE junction  
 Type II — Tumors originating within 2 cm of the squamocolumnar 
junction 
 Type III — Tumors of the subcardial region.  
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The origin of the tumor is sometimes unclear in patients who present with 
adenocarcinoma involving the GE junction. Patients with type I tumors are not 
appropriate candidates for a purely transabdominal approach. For type II or III 
tumors, a total gastrectomy may remove an adequate margin in the esophagus in 
patients with well- or moderately-differentiated histology.  
The surgical options for type I include an abdominal transhiatal gastric 
pull-up to the neck or an Ivor-Lewis-type operation (combined transthoracic and 
transabdominal approach).    
 Linitis plastica —  Linitis plastica has an extremely poor prognosis [76]. In one 
report, one-half of all patients had metastatic disease (mainly within the 
peritoneal cavity) at diagnosis [78]. Nodal involvement is frequent and extensive 
surgery may be required for complete excision [77,79]. One and seven year 
survival rates following gastrectomy were 50 and 8 percent, respectively [77]. 
Many surgeons consider the presence of linitis plastica to be a contraindication 
to potentially curative resection.  
Extent of lymph node dissection — One of the most controversial areas in the 
surgical management of gastric cancer is the optimal extent of lymph node 
dissection. Japanese surgeons routinely perform extended lymphadenectomy, a 
practice that some suggest at least partially accounts for the better survival rates 
40 
 
in Asian as compared to Western series [80]. The term "extended 
lymphadenectomy" variably refers to either D2 or D3 lymph node dissection.  
  The draining lymph node basins for the stomach can be divided into 16 
stations: stations 1 to 6 are perigastric, and the remaining 10 are located adjacent 
to major vessels, behind the pancreas, and along the aorta.  
 D1 lymphadenectomy refers to a limited dissection of only the perigastric 
lymph nodes.  
 D2 lymphadenectomy entails removal of nodes along the hepatic, left 
gastric, celiac and splenic arteries as well as those in the splenic hilum 
(stations 1-11).  
 D3 dissection includes nodes within the porta hepatis and periaortic 
regions (stations 1-16). Most Western surgeons classify disease in these 
regions as distant metastases, and do not routinely remove nodes in these 
areas during a potentially curative gastrectomy. 
Nevertheless, these data as well as those from other groups [81,82] suggest that 
D2 dissection can be performed safely with a perioperative mortality rate that is 
under 2 percent.  
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The conclusion of the MRC trial and Dutch trial (and its accompanying 
editorial [83] was that D2 lymph node dissection did not confer a benefit 
compared to D1 dissection, and could not be routinely recommended.    
Summary — Despite the results of randomized trials, major cancer centers 
frequently perform a D2 as compared to a D1 dissection, and treatment 
guidelines published by the National Comprehensive Cancer Network 
recommend that D2 lymph node dissection is preferred over a D1 dissection [65].  
If there is a survival benefit to be gained by extended lymphadenectomy, 
it requires that there be no added operative mortality. A pancreas and spleen-
preserving D2 lymphadenectomy provides superior staging information, and 
may provide a survival benefit while avoiding its excess morbidity. Splenectomy 
during gastric resection for tumors not adjacent to or invading the spleen 
increases morbidity and mortality without improving survival [84]. Thus it is not 
recommended unless there is direct tumor extension.  
Adjuvant and neoadjuvant therapy — While complete resection provides the 
best chance for long-term survival, more than one-half of patients will have 
regional node involvement at the time of resection. Five-year survival rates are 
approximately 10 percent with N3 disease, 10 to 15 percent with N2 disease, and 
50 percent with T3N0 disease[85]. These poor results with surgery alone, 
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especially in patients with nodal metastases, provide the rationale for adjuvant 
and neoadjuvant approaches using chemotherapy, radiation therapy (RT), or a 
combination of the two.  
Adjuvant chemoradiotherapy — The benefit of postoperative adjuvant 
combined modality therapy using contemporary RT techniques and leucovorin-
modulated 5-fluorouracil was shown in a United States Intergroup study (INT-
0116). The trial included patients with GE junction adenocarcinomas that 
extended at least 2 cm into the stomach.   
Three-year overall survival and disease-free survival were significantly 
better for patients receiving chemoradiotherapy (52 versus 41 percent, and 49 
versus 32 percent, respectively). These results have been considered by many to 
have changed the standard of care in the United States.   
 Neoadjuvant chemotherapy and chemoradiotherapy — The goals of 
preoperative therapy are to increase the resectability rate, reduce the rate of local 
and distant recurrences, and ultimately improve survival. Data from several 
uncontrolled series suggest that some patients with initially locally advanced 
disease may respond to chemotherapy or chemoradiotherapy sufficiently that 
they are able to undergo potentially curative surgery.  Clinicians  who treat 
gastric cancer have a bias towards neoadjuvant therapy for two major reasons. 
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First, the ability to deliver adequate postoperative therapy may be compromised 
by complications of the surgery. Between one-third and one-half of patients do 
not recover quickly enough to tolerate adjuvant treatment within four to six 
weeks of surgery.  
Second, some patients have aggressive disease and develop metastases 
within a short period of time, despite having an adequate operation. These 
patients do not benefit from surgery, and the delay in operative intervention with 
neoadjuvant therapy may have permitted their identification prior to exploratory 
laparotomy, thus sparing them unnecessary surgery.  
If the posttherapy restaging evaluation demonstrates no evidence of 
metastatic disease, these patients are considered eligible for potentially curative 
surgery. When feasible, patients should be enrolled on therapeutic trials 
evaluating the benefit of neoadjuvant or adjuvant therapies.  
Prognosis —  The following five-year survival rates were reported in a series of 
750 patients from MSKCC, in whom more than 15 lymph nodes were examined 
[17]: IA — 95 percent IB — 85 percent II — 54 percent IIIA — 37 percent IIIB 
— 11 percent IV — 7 percent  
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              Somewhat lower five-year survival rates were reported in the National 
Cancer Data Base [66]: IA — 78 percent IB — 58 percent II — 34 percent IIIA 
— 20 percent IIIB — 8 percent IV — 7 percent  
Palliative gastrectomy — In patients with locally advanced or metastatic 
disease, surgical intervention may provide effective palliation of symptoms such 
as pain, nausea, bleeding, or obstruction. Palliative  gastrectomy can provide 
symptomatic relief, and a possible improvement in survival, although this is 
controversial. The criteria for selection of patients who may benefit from 
palliative gastrectomy are not firmly established.   
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AIM   OF  THE  STUDY 
 
1. To  study   the  epidemiology  of  cancer    stomach . 
 
2. To  assess  the influence of   risk factors  in  the  causation  of  cancer stomach. 
 
3. To   correlate  the   clinical  features  of  cancer stomach with  the  site  of  lesion. 
 
4. To  assess  the commonest  anatomical  site  of lesion in cancer stomach. 
 
5. To  assess  the  incidence  of  operability  of  tumour  at  the  time  of  
presentation. 
 
6. To assess  the role of  CECT in staging the cancer stomach. 
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MATERIALS  AND METHODS 
                           Patients  included   in  the  study  were  recruited  from  the  
Department  of  Digestive  Health  and  Diseases,  Government  Peripheral  
hospital,  Anna Nagar, Chennai. The  study  period  was  from  January 2008  to  
December 2009. 
                         Consecutive  patients  diagnosed  to  have  cancer stomach   were 
included  in  the study  group. Only biopsy proven  adenocarcinomas,  were 
included in the study. A detailed proforma was  compiled  for   the patients with 
cancer stomach. A  detailed  history  about   dietary  habits,  social  habits  such  
as  smoking,  alcohol  ,previous gastric surgery , previous history of gastric ulcer 
and family history of gastric cancer were  recorded. Clinical  history  about  
dyspepsia,  pain abdomen,  anorexia  and  weight  loss, vomiting, dysphagia and 
upper GI bleed  were  obtained and thorough  clinical  examination was  done. 
Body mass index was calculated for all. 
                         Appropriate investigations such as haemoglobin, erythrocyte 
sedimentation rate, X ray chest, U G I Scopy   &  biopsy  and  CECT scan of the  
upper  abdomen were  done.   Histopathological  grading  was  done  by  the  
pathologist. Treatment  was   individualized  according  to  the  stage  of  the  
disease  during  presentation.   
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                           The  statistical  analysis of the data  was  done  using  SSPS 11.  
‘ p’ value  of < 0.05  was  considered to  be  statistically significant. The p value 
was calculated using chi square test.  Percentage  calculation  and cross analysis  
were   done  to identify significant data. 
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RESULTS 
                      During the study period of  two years, a total number 12800 
patients attended OPD. Endoscopy was performed for  5842 cases (31%). Among 
those, biopsy proven adenocarcinomas  was  172. This accounts to 3% of total 
endoscopy and 1% of total OPD cases. Of these 172 cases, males were 72% and 
females 28% constituting  a   ratio of   3: 1. 
                            The  incidence  of  cancer  stomach in  patients  below  the  age  
of  40  years was 13.95%. It  slowly  increased  and  reached a maximum in the 
5th  decade  and  then  slowly  declined. The  incidence   was  13.3%  in  patients  
above  the  age  of  70. The mean age of the patient was 55.76. The minimum age 
was 28yrs and the maximum age was 77years. 
                               Most  of  them  were  from  places  in  & around Chennai 
(88%).  Many  of  them were  farmers  and  labourers.  About  80%  of  the  
female  patients  were  housewives. Majority  of  the  patients were Hindus ( 
89.5%), followed  by Muslims (6%)  and Christians  ( 4.5%). 
 RISK  FACTORS 
                                One  patient    had  family history  of  cancer  stomach. He 
had growth even before the age of 40years. No patient had previous documented 
history of  gastric ulcer. Around 7% of them had previous history of gastric 
surgery. Alcoholics and smokers formed 46.5% & 61.6% respectively. 71.5%  
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had consumed high salt diet and 71.5% had not consumed fresh vegetables. Also 
these  patients did not use  refrigerators.   
                  Abdominal pain  was  present  in 61.%  of  patients but 
anorexia was only second to pain abdomen with 39-46%. Other common 
presentations were vomiting in 38.5%, indigestion in 40%, and early satiety in 
18.6%. Even though ball rolling movement is a symptom of complicated peptic 
ulcer disease, 18% of cancer stomach patients had significance in curative lesions 
and early presentation to hospital. Less common symptoms like awareness of 
lump (12.8%), abdomen distension (8.7%),  and  GI bleed (6%) were  also 
recorded.  
Clinical findings - Body Mass Index was < 19 in  88.34% of  patients . Only  one   
patient  had palpable supra clavicular lymph node. None had cutaneous markers 
of intra abdominal malignancy. 19  patients had epigastric lump,  14    had  
ascites & 11  had  hepatomegaly.  CVS  &  RS  were normal in all cases. 
Investigations 
                             Haemoglobin  was  low  in 65.7% of  cases &  77.9% had  
raised  ESR.  55.8% of cases had  blood group “A”. 
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EPIDEMIOLOGY 
 
NO OF PATIENTS  PERCENTAGE 
TOTAL 172 100 
Age Group 
  
BELOW 40 24 13.95 
41-50YRS 39 22.67 
51-50urs 44 25.58 
above 60yrs. 65 37.79 
SEX 
  
MALE 123 71.5 
FEMALE 49 28.5 
RESIDENCE 
 
CHENNAI 152 88 
OUTSIDE CHENNAI 20 12 
RELIGION 
 
HINDU 154 89.5 
CHRISTIAN 8 4.5 
MUSLIM 10 6 
SYMPTOM ANALYSIS 
 
NO OF PATIENTS PERCENTAGE 
PAIN ABDOMEN 105 6100% 
INDIGESTION 67 39 
EARLY SATIETY 32 18.6 
LOSS OF APPETITE 67 39 
LOSS OF WEIGHT 79 46 
NAUSEA/VOMITING 66 38.5 
AWARENESS OF LUMP 19 11 
BRM 31 18 
ABDOMEN DISTENSION 15 8.7 
DYSPHAGIA 22 12.8 
JAUNDICE 1 0.6 
UGI BLEED 13 7.6 
SIGNS 
PALLOR 123 71.5 
JAUNDICE 1 0.6 
SUPRACLAVICULAR 
NODE 1 0.6 
ABDOMINAL SCAR 12 7 
EPIGASTRIC MASS 19 11 
HEPATOMEGALY 11 6.4 
ASCITES 14 8.1 
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RISK FACTOR ANALYSIS 
 
NO OF PATIENTS PERCENTAGE 
PREVIOUS GASTRIC 
SURGERY 12 7 
H/O GASTRIC ULCER 0 0 
SMOKING 106 61.6 
ALCOHOL 80 46.5 
FAMILY H/O GASTRIC 
CANCER 1 0.6 
HIGH SALT DIET 123 71.5 
NO 
REFRIGERATOR/FRESH 
FRUITS 
123 71.5 
INVESTIGATIONS 
 
 
NO. OF PATIENTS PERCENTAGE 
HEMOGLOBIN <9 
(ANAEMIA) 113 65.7 
BLOOD GROUP - 'A' 96 55.8 
ESR >30 134 77.9 
   
VOGD 
SITE OF LESION NO.OF PATIENTS PERCENTAGE 
ANTRAL GROWTH 94 54.65 
MID BODY GROWTH 38 22 
OG JUNCTION GROWTH 26 15 
DIFFUSE GASTRIC 
CANCER 14 8.35 
GOO 
YES 56 
 
NO 40 
 
CT SCAN NO.OF PATIENTS PERCENTAGE 
NORMAL 62 36.05 
ASCITES 8 3.6 
LYMPH NODES (N1+) 42 24.42 
LIVER SECONDARIES 7 5.8 
L.NODES +SEC/ASCIRES 7 4 
T4 LESIONS 43 26.13 
TREATMENT 
CURATIVE 62 36.05 
PALLIATIVE 110 63.95 
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SITE OF LESION IN ENDOSCOPY                        
               UGI Scopy   was  done  for  all  cases and it was found that antral 
growth was present in 60%(p<0.001**), midbody growth in 20%, OGJunction 
growth in 12% and diffuse gastric cancer in 8%. 60% of antral growth presented 
with GOO. A point to be noted is that 50% of antral growth was found to be 
operable at the time of diagnosis (p<0.001**) due to its early presentation. 
Whereas most of the OGJunction growth(80.8%) and diffuse gastric 
cancer(92.9%) were inoperable at the time of presentation(p<0.001**)           
Sit of 
Lesion 
No. of 
patients % 
Curative 
(%) Palliative p value Significance 
ANTRAL 94 54.65 49.9 51.1 
  
MID 38 22 26.3 73.7 
  
OG 26 15 19.2 80.8 
  
DIFFUSE 14 8.35 7.1 92.9 
  
     
<0.001** Very significant 
 
CT scan in staging 
       CT scan abdomen is the investigation to stage the cancer stomach used 
world wide until now. In this study CTscan staging showed  36% of  cases in an 
operable stage and 67% in an inoperable stage (p<0.001**), thus avoiding  
unnecessary laparotomy.                               
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CROSS ANALYSIS OF PRESENTING SYMPTOM Vs TYPE OF GROWTH 
(SUB GROUP ANALYSIS) 
 
ANTRAL 
GROWTH 
MIDBODY 
GROWTH OGJ DIFFUSE 
P 
VALUE SIGNIFICANCE 
SYMPTOMS VS SITE OF LESION 
PAIN ABDOMEN(%) 69 50 50 57 0.113 NOT SIGNIFICANT 
INDIGESTION 45.7 15.8 15.4 100 <0.001** VERY SIGNIFICANT 
EARLY SATIETY 24.5 13.2 7.7 14.3 0.164 NS 
LOSS OF APPETITE 39.4 39.5 46.2 21.4 0.496 NS 
LOSS OF WEIGHT 47.9 47.4 42.3 35.7 0.825 NS 
NAUSEA/VOMITING 44.7 21.1 34.6 50 0.061 NS 
AWARENESS OF LUMP 11.7 13.2 7.7 7.1 0.866 NS 
BRM 24.5 7.9 7.7 21.4 0.063 NS 
ABDOMEN DISTENSION 9.6 2.6 3.8 28.6 0.022* SIGNIFICANT 
DYSPHAGIA 2.1 5.3 61.5 14.3 <0.001** VERY SIGNIFICANT 
JAUNDICE 1.1 - - - 0.841 NS 
UGI BLEED 9.6 5.3 3.8 7.1 0.717 NS 
RISK FACTOR VS SITE OF LESION 
PREVIOUS GASTRIC 
SURGERY 9.6 2.6 3.8 7.1 0.479 NS 
H/O GASTRIC ULCER 0 0 0 0 - NS 
SMOKING 63.8 60.5 61.5 50 0.798 NS 
ALCOHOL 48.9 42.1 46.2 42.9 0.897 NS 
HIGH SALT DIET 70.2 73.7 73.1 71.4 0.978 NS 
NO 
REFRIGERATOR/FRESH 
FRUITS 
70.2 73.7 73.1 71.4 0.978 NS 
CL.FEATURES VS SITE OF LESION 
PALLOR 70.2 73.7 73.1 71.4 0.978 NS 
JAUNDICE 1.1 - - - 0.841 NS 
ABDOMINAL SCAR 9.6 2.6 3.8 7.1 0.479 NS 
EPIGASTRIC MASS 11.7 13.2 7.7 7.1 0.866 NS 
HEPATOMEGALY 6.4 - 19.2 - 0.013* SIGNIFICANT 
ASCITES 8.5 2.6 3.8 28.6 0.018* SIGNIFICANT 
INV VS SITE OF LESION 
BLOOD GP 'A' 38.3 55.3 96.2 100 <0.001** VERY SIGNIFICANT 
ESR >30 77.7 76.3 80.8 78.6 0.979 NS 
HB <9 64.9 68.4 69.2 57.1 0.861 NS 
OPERABILITY VS VOGD 
CURATIVE (%) 48.9 26.3 19.2 7.1 
  
PALLIATIVE 51.1 73.7 80.8 92.9 <0.001** VERY SIGNIFICANT 
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 In this study dysphagia was predominantly present in OGJunction 
growth(p<0.001) which is very significant.       
 In the cross analysis indigestion was present in 45% of antral growth and 
in all  cases of  diffuse gastric cancer which is also statistically very 
significant (p<0.001).  
 Ascites was a presenting feature in 30% of  diffuse gastric cancer in cross 
analysis, which was  also statistically  significant(p=0.022*). 
In this study Blood group A was present in all cases of  diffuse gastric cancer 
and  96% of  OGJunction  cancers in cross analysis, which was  also statistically  
very significant(p=0.001*). 
In  this study two third  of  all  types of  gastric  cancers were  inoperable in  
the pre-operative CT evaluation, which was   statistically  significant(p<0.001).   
In the sub group  93%,  81% and 70% of  diffuse gastric cancer, OGJ 
growth and mid body  growth respectively, in descending order,  were inoperable 
whereas antral growth was operable in 50%. This is statistically very 
significant(p<0.001**).       
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DISCUSSION 
                  Cancer stomach is one of the commonest digestive tract cancers in 
and around Chennai. Malhotra et al reported  that The  incidence rate of gastric 
cancer is four times higher in Southern India compared with Northern India[90]. 
Among the six registries, the highest incidence in both sexes is reported from 
Chennai and the lowest from Barshi. 
                    The mean age of carcinoma stomach in this study was 55.8 years. 
Jayanthi V et al from Chennai reported similar age group in her study in 
2007[88]. Ferlay[1],Parkin[3] and Henderson[86] et al in their report stated  that  the 
age at initial presentation was 70 years which was  similar to this present study.  
Kurihara et al reported that in countries with high incidence of gastric cancer, the 
age at diagnosis tends to be a decade earlier.[87]  
              The male female ratio in this  study was 3:1similar  to that quoted  by 
Jayanthi V[88] et al & Ferlay[1] et al. Jayanthi.V[88]et al reported that gastric 
cancer predominantly affected male with an overall ratio of 3(p=0.001) which 
was very significant as in this study. Ferlay[1],et al reported that  Worldwide  
gastric cancer rates are about twice as high in men as in women.  
                  In the present study, gastric cancer was more common among the 
Hindus, followed by Muslims and then Christians. The Mumbai cancer registry 
had reported a preponderance among Hindus & Muslims with a low incidence 
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among Christians.  Siddiqi et al in his study showed significant differences in 
Hindus, Muslims and Sikh population. Muslims  had highest incidence in his 
study. [91]     
Risk  factors analysis                                  
                  In western countries, a causal relationship has been established with 
the consumption of alcohol and smoking. In this study 61.6% of the cases had   
smoking habit which was a significant risk factor in males. Similar reports were 
showen by Gajalakshmi C.K.et al in the year 2001.In a case–control study from 
Chennai,smokers had a twofold increased risk of gastric cancer compared to 
nonsmokers, and the risk seen among current smokers was significantly higher 
than that among ex-smokers. The risk among those who smoke “bidi” (a type of 
local cigarette made from suncured tobacco that is rolled in a rectangular piece of 
dried leaf of Diospyros melanoxylon) was thrice as that  among cigarette 
smokers. [92].  
                  Sumathi B.et al showed pickled food consumption as an independent 
risk factor for the development of gastric cancer, while consumption of pulses 
was protective[93]. Tatematsu et al showed that high salt intake damages stomach 
mucosa and increases the susceptibility to carcinogenesis in rodents [26]. Shikata, 
K et al showed that the risk of high salt intake was strongest in patients who had 
both H. pylori infection and atrophic gastritis [27]. In this study around 71.5% had 
57 
 
consumed high salt diet and 71.5% had not consumed fresh vegetables. Also 
these patients had  no   refrigerators which was also an important risk factor both 
in males and females.    
                 Zhao et al showed a genetic predisposition to gastric cancer has been 
repeatedly confirmed[41]. Bonney A genetic predisposition for chronic atrophic 
gastritis, a precursor of gastric carcinoma, has been described and may account 
for at least some cases of familial gastric cancer [42]. But in this study only one 
patient had  family history of gastric cancer which was diffuse gastric cancer. He 
had growth even before the age of 40years. Role of genetics in cancer stomach 
needs further evaluation in our country. 
                 Hansson, et al, concluded that despite the known associations between 
H. pylori infection and peptic ulcer disease and H. pylori infection and gastric 
cancer, the association between benign gastric ulcer disease and gastric cancer 
remains controversial [46].In this study none of our  patients had previous history 
of  gastric ulcer. Nomura  et al assessed  there is an increased risk of gastric 
cancer after gastric surgery, with the risk being greatest 15 to 20 years after 
surgery and then increasing with time [34]. In this study around 7% of them had 
previous history of gastric surgery. It shows that previous gastric surgery  is still 
a continuing risk factor. 
58 
 
Even though there were many risk factors in a large number of cases, 
nothing is statistically  significant  in the cross analysis . 
Symptom  analysis 
               Wanebo et al and Sleisenger Text Book of Gastrointestinal and Liver 
Disease clearly states that Weight loss (62%) and persistent abdominal pain 
(52%) are the most common symptoms during initial diagnosis [53]. Contradictory 
to that in this study Abdomen pain was  present  in 61.%  of  patients but 
anorexia and weight loss was only second to pain abdomen with 39-46%. Other 
common presentations were vomiting in 38.5%, indigestion in 40%, and early 
satiety in 18.6%. Contradictory to the belief that ball rolling movement is a 
symptom of complicated peptic ulcer disease, this was seen in 18% of growth 
stomach in the current study. But it had a significance in curative lesions and 
early presentation to hospital. Rare and late presentations like awareness of lump 
in 12.8%, abdomen distension in 8.7%,  and  GI bleed in 6% were  also recorded. 
    According to Tucker et al tumors affecting the cardia (OGJunction) can 
cause dysphagia.[98]  In our study dysphagia predominantly was found in 
OGJunction growth with p<0.001  which is very significant.   
              In cross analysis indigestion was present in45% of antral growth and in 
all cases of diffuse gastric cancer acquiring a very significant p value of <0.001.   
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Clinical findings 
              Pallor presented in two third of cases, yet not significant. This may be 
because of nutritional deficiency due to decreased intake and the bleeding from 
tumor. 
              Supraclavicular node and jaundice were present only in one case each. 
Also cutaneous markers of intra abdominal malignancy were not noted. There are 
only a few case reports regarding this in literature. Larger study is needed. 
              Secondaries liver presenting as hepatomegaly was more common with 
OGJunction  cancers with a value of around 20%  which was statistically  
significant(p=0.018*). 
              Ascites a presenting feature in 30% of diffuse gastric cancer was  also 
found to be  statistically  significant(p=0.022*) in cross analysis,  
 Arid et al  showed individuals of blood group A have been known for decades to 
show an approximately 20 percent higher risk of gastric cancer than those of 
groups O, B, or AB [40].   Langman et al suggest that group A may be particularly 
associated with the diffuse type of gastric cancer [39]. In this study Blood group A 
was present in almost all cases of diffuse gastric cancer and  96% of  OG 
Junction  cancers with a statistically  very significant value p=0.001*. 
              Kampschoer et al and  Powell et al demonstrated in their analysis that  
despite the decline in gastric cancer, overall there has been an explosive increase 
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in incidence of cancer of the gastric cardia[8-10].  Correa P et al showed that in 
the United States, the distribution of gastric cancer within the stomach is 39% in 
the proximal third, 17% in the middle third, 32% in the distal third, and 12% 
involving the entire stomach [95].  The decline in gastric cancer rates reflects a 
drop in the rate of distal gastric cancers. 
              In India also a trend towards an increase in the incidence of cardia 
tumors is seen. This is evident in the data from Mumbai, where the percentage of 
cardia and fundus tumors increased from 13% in 1941–1968 to 23% in 1987–
1993 shown by Mohandas KM et al [95]. 
              In this study antral growth was present in 60% (p<0.001), midbody 
growth in 20%, OGJunction growth in 12% and diffuse gastric cancer in 8%.  
On endoscopy around 60% of patients had antral growth which is contradictory 
to western data where OGJunction growth is more common i.e., around 39%[95]. 
This study is supported by Jayanthi V.et al who showed similar incidence of 
67% antral growth, mid body 23%, cardia&OG Junction  growth 10%[88].  
               This may be because of a large low socioeconomic group in India, a 
developing country. Moreover food habits here differ from western people. 
Lastly the most important factor, H.Pylori is 100% prevalent in developing 
countries among the age group of 20yrs.  
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               Around 60% of antral growth presented with GOO. Another point to be 
noted is that around 50% of antral growth was found to be operable at the time of 
admission (p<0.001**) due to its early presentation. On the contrary most of the 
OG Junction growth (80.8%) and diffuse gastric cancer (92.9%) were inoperable 
during that time. 
                Haemoglobin was low in 65.5% and ESR raised in 77% of cases which 
were not statistically significant. 
CT scan in staging  
      Grote R et al showed that CT abdomen has a sensitivity of 65% to 
90% for advanced gastric cancer[97]. The accuracy rate was approximately 60% to 
70% for T staging  and between 40% and 70% for N staging. CT scan abdomen 
is the investigation to stage the cancer stomach used world wide until now. In this 
study CTscan staging showed 36% of cases in operable and 67% in inoperable 
stages. Thus unnecessary laprotomy can be avoided.        
TREATMENT 
      Mohandas et al showed that in India more than 90% of all gastric 
cancers are being diagnosed in an advanced stage, and in those subjected to 
surgery more than 70% have serosal infiltration[96]. In this study two third of all  
types of gastric  cancers were  inoperable in the pre-operative  CT evaluation and 
this has a very statistical  significance. (p<0.001**).           
62 
 
CONCLUSION 
  Mean age of the patients with cancer stomach is 56 years. 
 Males outnumbered female cases probably due to increased smoking and alcohol 
consumption. 
 People with Low intake of vegetables and fruits and those who had no 
refrigerators lead to a higher risk of developing cancer stomach in both sexes. 
 Past history of gastric surgery still continues to be a risk factor. And gastric ulcer 
is not a significant risk factor. 
 Pain abdomen is the commonest presenting symptom. 
  Significant number of patients with Ball Rolling Movement were found to 
be operable in the pre-operative evaluation. 
 Dysphagia and vomiting immediately after taking food along with loss of 
appetite  commonly present  as OG Junction growth. 
 Cutaneous  markers  of intra abdominal malignancy are extremely rare. 
  Antral growth is more common   than  OG Junction growth. 
  Antral growth  presents earlier and more amenable to surgery compared to 
OGJunction and  diffuse gastric cancer. 
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   Blood  group “A” is a significant risk factor for cancer stomach 
particularly for diffuse  gastric cancer and OGJunction  growth.  
  CT Scan is a valuable modality of investigation preoperative evaluation. 
 Two thirds of patients were found to be inoperable during the time of diagnosis  
and  hence  underwent only palliative treatment. 
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MASTER CHART 
SNO DDHO NAME AGE SEX Abd.pain indig E..Sati lOA LOW vomit lump BRM Abd.dis dysph Jaun bleed Pallor scar mass live ascites HB BL.GP ESR VOGD CT_SCAN TREAT 
1 47/08 KPK MENON 75 1 2 2 2 1 1 1 2 2 2 1 2 2 2 2 2 1 2 2 1 2 3 A 1 
2 73/08 EKAMBARAM 63 1 1 1 1 1 1 1 2 2 2 1 2 2 1 2 2 2 2 1 1 1 3 E 2 
3 188/08 VEDIAPPAN 65 1 1 1 1 1 1 1 2 2 1 2 2 2 1 2 2 2 1 1 1 1 1 E 2 
4 202/08 EZHUMALAI 63 1 1 2 2 1 1 2 2 1 2 2 2 2 1 2 2 2 2 1 2 1 1 A 1 
5 250/08 RENGANAYAKI 53 2 1 2 2 1 1 2 1 2 2 2 2 2 1 2 1 2 2 1 2 1 1 A 2 
6 2012/07 MOORTHI 42 1 2 2 2 2 2 2 2 2 2 2 2 1 1 2 2 2 2 1 1 1 2 F 2 
7 348/08 PERUMAL 64 1 2 1 2 2 2 2 2 2 1 2 2 2 1 1 2 2 1 1 1 1 4 B 2 
8 426/08 MANICKAM 65 1 1 2 2 2 1 2 2 2 2 2 2 2 1 2 2 2 2 1 2 1 1 A 1 
9 433/08 SUNDARAMBAL 75 2 2 1 1 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 1 1 1 C 2 
10 4879/08 BALAKRISHNAN 62 1 1 1 1 1 1 2 2 2 2 2 1 2 1 1 2 1 2 1 2 1 1 A 1 
11 535/08 YUVARAJ 53 1 2 2 2 1 1 1 1 2 2 2 2 2 1 2 1 2 2 1 1 1 3 A 1 
12 644/08 HYAD BASHA 42 1 1 1 2 2 2 1 2 2 2 2 2 1 1 2 2 1 2 1 1 1 1 C 2 
13 775/08 RAJENDRAN 52 1 2 2 2 1 1 2 2 2 2 1 2 2 1 2 2 1 2 1 1 1 3 D 2 
14 727/08 MANICKAM 65 1 2 1 2 1 1 1 1 1 2 2 2 2 2 2 1 2 2 2 2 2 1 A 1 
15 857/08 CHINNAPAN 46 1 2 2 2 1 2 1 2 2 2 2 2 2 1 2 2 2 2 1 2 1 2 F 2 
16 858/08 PALANIVEL 48 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 1 1 2 A 1 
17 419/08 NANDAGOPAL 64 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 4 C 2 
18 1162/08 DEIVANAI 55 2 1 2 2 1 1 1 2 2 2 2 2 2 1 2 2 2 2 1 2 1 1 C 2 
19 1261/08 GANESAN 50 1 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 C 1 
20 1524/08 KANNIAMMAL 60 2 1 2 2 2 1 2 2 2 2 1 2 2 2 2 2 2 2 2 1 2 3 C 2 
21 1695/08 ABDHUL KADHEER 65 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 1 1 3 F 2 
22 1670/08 PADMANABAN 61 1 1 2 2 1 2 2 1 2 2 2 2 2 2 2 1 2 2 2 1 2 1 F 2 
23 1791/08 MURUGESAN 35 1 1 1 2 2 1 1 2 2 1 2 2 2 1 2 2 2 1 2 1 1 4 B 2 
24 1814/08 MAHALINGAM 50 1 1 2 2 2 2 1 2 2 2 2 2 2 1 2 2 2 2 1 1 1 3 A 1 
25 1857/08 RADHAKRISHNAN 47 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 1 1 1 A 1 
26 1873/08 SUNDARRAJAN 37 1 2 2 2 1 1 2 2 2 2 1 2 2 1 2 2 2 2 1 1 1 3 C 2 
27 1722/08 DASS 62 1 1 2 2 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 1 1 A 1 
28 1899/08 KUPPAMMAL 56 2 1 2 2 1 1 2 2 2 2 2 2 2 1 2 2 2 2 1 1 1 2 C 2 
29 1875/08 JAYARAMAN 48 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2 1 1 A 1 
30 1749/08 VEERAMMAL 45 2 1 1 1 1 2 2 2 1 2 2 2 2 1 2 2 2 2 1 2 1 2 F 2 
31 2172/08 SIVALINGAM 40 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 1 2 2 2 1 2 1 F 2 
32 2206/08 PATCHIAPPAN 45 1 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 1 2 3 F 2 
33 2304/08 VENKATESH 68 1 1 1 2 1 2 2 2 2 2 1 2 2 1 2 2 2 2 1 1 1 3 C 2 
34 2447/08 MUNIAMMAL 50 2 1 1 2 1 1 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 1 A 1 
35 2510/08 DEIVASIGAMANI 45 1 2 1 2 1 1 1 2 2 2 1 2 2 1 2 2 2 2 1 1 1 3 C 2 
36 2449/08 KUMARI 37 2 1 1 2 2 2 1 1 2 2 2 2 2 2 2 1 2 2 2 1 2 1 A 1 
37 2539/08 MURUGAN 40 1 2 1 1 2 1 1 2 1 2 2 2 2 1 2 2 2 2 1 1 1 1 A 1 
38 2549/08 ELUMALAI 57 1 1 2 2 1 1 2 2 2 2 2 2 2 2 1 2 2 2 2 2 1 1 A 1 
39 2739/08 RAMANATHAN 61 1 1 2 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 C 2 
40 2799/08 PATHARUNISHA 40 2 1 1 2 2 2 2 2 1 2 2 2 2 1 2 2 2 2 1 1 1 4 F 2 
41 3013/08 KOLLAPURI 74 1 1 1 1 1 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1 A 1 
42 2950/08 VELU 68 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2 1 1 A 1 
43 3165/08 PALANI 50 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 1 1 A 1 
44 3177/08 NARAYANAN 61 1 2 1 1 2 2 2 2 2 1 2 2 2 1 2 2 1 1 1 2 1 1 E 2 
45 3250/08 MARIAMMAL 46 2 2 2 2 1 2 2 2 2 1 1 2 2 2 2 2 2 1 2 2 2 2 B 2 
46 3326/08 GEETA 40 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 3 F 2 
47 3345/08 VARADHAN 70 1 1 2 2 2 1 1 2 2 2 2 2 2 1 2 2 2 2 1 2 1 1 C 2 
48 3621/08 SELVARAJ 38 1 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 1 2 2 2 1 C 2 
49 3379/08 AUBRAJ 48 1 1 2 2 2 2 1 2 2 2 2 2 1 1 2 2 2 2 1 1 1 1 C 2 
50 3560/08 SEENIVASAN 48 1 1 2 2 2 1 2 2 2 2 2 2 2 1 2 2 2 2 1 2 1 2 F 2 
51 3729/08 VAITHIYANATHAN 61 1 1 2 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2 2 2 1 2 A 1 
52 4113/08 GANDHIMATHI 59 1 1 2 2 2 1 2 1 2 2 2 2 2 2 2 1 2 2 2 1 2 2 F 2 
53 4162/08 DEVENDRAN 59 1 1 1 1 1 1 2 2 2 1 1 2 2 1 2 2 2 1 1 2 1 1 C 2 
54 4182/08 MANICKAM 50 1 1 2 2 2 1 1 2 2 2 2 2 2 1 2 2 2 2 1 2 1 1 C 2 
55 4312/08 SARAVANAN 71 1 1 1 2 1 1 1 1 1 2 2 2 2 1 2 1 2 2 1 1 1 1 C 2 
56 4303/08 MOHANDOSS 40 1 1 2 2 2 1 2 1 2 2 2 2 2 1 2 1 2 2 1 1 1 2 F 2 
57 4383/08 SAROJA 65 2 1 1 1 2 2 2 2 1 1 2 2 2 1 2 2 2 1 2 2 1 1 A 1 
58 6345/08 ARUMUGAM 73 1 2 2 2 2 2 1 2 2 2 1 2 2 1 2 2 2 2 1 1 1 3 A 1 
59 4400/08 SUBBRAMANI 77 1 1 1 2 2 2 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2 1 C 2 
60 4427/08 AJMUNISHA 70 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 F 2 
61 4305/08 SELVAMANI 36 1 1 1 2 2 2 1 2 2 2 2 2 2 1 2 2 2 2 1 1 1 1 F 2 
62 4439/08 ALLIMUTHU 30 1 2 1 2 2 1 2 2 2 1 2 2 1 2 2 2 2 1 2 1 2 4 F 2 
63 4618/08 MARY 47 2 1 2 2 1 1 1 2 2 2 1 2 2 2 2 2 1 2 2 1 2 3 F 2 
64 4690/08 PARVATHI 45 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 1 1 2 D 2 
65 4860/08 RATHINAMALA 65 2 2 1 2 1 2 1 2 2 1 1 2 2 1 2 2 2 1 1 1 1 4 B 2 
66 4636/08 GOVINDAN 53 1 1 1 1 2 2 1 2 1 2 2 2 2 1 2 2 2 2 1 2 1 1 A 1 
67 4728/08 MARIAPPAN 40 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 1 F 2 
68 4853/08 SANKARI 50 2 1 1 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 4 F 2 
69 4790/08 MARUDHARAJ 60 1 1 1 1 1 1 2 1 1 2 2 2 1 2 2 1 2 2 2 2 2 1 A 1 
70 4852/08 BALAKRISHNAN 61 1 1 1 1 1 1 1 2 1 2 2 2 2 2 2 2 2 2 2 1 1 1 A 1 
71 4728/08 MARIAPPAN 40 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 1 A 1 
72 4940/08 SUBBRAMANI 57 1 1 1 1 1 1 1 2 2 2 2 2 2 1 2 2 2 2 1 1 1 2 F 2 
73 5034/08 KAMALA 70 2 1 1 2 2 1 2 2 2 2 2 2 2 1 2 2 2 2 1 1 1 1 F 2 
74 2569/08 PATCHIAMMAL 34 2 2 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2 1 1 C 2 
75 5130/08 RAVANAMMA 35 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2 1 2 F 2 
76 5214/08 AIYASAMY 60 1 1 1 1 1 1 1 2 1 2 2 2 2 2 2 2 2 2 2 1 2 2 A 1 
77 5189/08 RADHAKRISHNAN 40 1 2 2 2 2 2 2 2 2 2 2 2 2 1 1 2 2 2 1 2 1 1 A 1 
78 5749/08 RAZIYA BEGAM 68 2 2 2 2 1 2 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2 1 C 2 
79 5113/08 RUCKMANI 65 2 2 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 1 1 1 C 2 
80 5324/09 VARADHARAJAN 41 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 F 2 
81 4690/08 PARVATHI 40 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2 1 2 F 2 
82 5852/08 THATHIYAN 74 1 2 1 1 2 1 1 2 2 2 2 2 2 1 2 2 2 2 1 1 1 4 A 1 
83 5394/08 CHINNAPAIYAN 66 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 1 1 2 F 2 
84 5561/08 DEVAKIRUBAI 45 2 1 1 2 2 2 1 1 1 2 2 2 2 1 2 1 2 2 1 1 1 4 D 2 
85 5738/08 SANKARLAL 60 1 2 2 2 1 1 1 2 2 2 2 2 2 1 2 2 2 2 1 1 1 1 A 1 
86 5749/08 KANNIAMMAL 60 2 1 2 2 1 1 1 1 2 2 2 2 2 1 2 1 2 2 1 2 1 2 A 1 
87 6047/08 DHANALAKSHMI 47 2 2 1 1 2 2 1 2 1 2 2 2 2 1 2 2 2 2 2 1 1 4 F 2 
88 6143/08 RAMAREDDY 65 1 2 2 1 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 1 1 1 A 1 
89 6215/08 GANESAN 64 1 1 1 2 2 1 2 2 2 2 2 2 2 1 2 2 2 2 1 2 1 1 C 2 
90 6370/08 LEENA 50 2 1 1 2 2 2 1 2 2 2 2 2 2 1 2 2 2 2 1 2 1 1 C 2 
91 6412/08 ELUMALAI 58 1 1 1 1 2 1 2 2 1 2 2 2 2 1 2 2 2 2 1 1 1 1 A 1 
92 6547/08 JAYARAMAN 70 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2 1 1 A 1 
93 6551/08 KRISHNAN 58 1 1 1 2 2 2 2 2 1 2 2 2 2 1 2 2 2 2 1 2 1 1 A 1 
94 6253/08 ARUMUGAM 46 1 1 1 1 2 1 2 1 1 2 2 2 2 1 2 1 2 2 2 1 1 3 C 2 
95 6294/08 PANNER SELVAM 40 1 2 1 1 2 2 2 2 1 2 2 2 2 1 2 2 2 2 1 2 1 1 A 1 
96 4117/08 RAMADOSS 53 1 1 1 2 2 1 2 2 2 2 2 2 2 1 1 2 2 2 1 1 1 1 C 2 
97 2232/08 RADHA 47 2 2 2 2 2 1 2 2 2 2 2 2 2 1 2 2 2 2 1 1 1 2 F 2 
98 6388/08 GANESAN 70 1 1 2 2 2 1 2 2 2 2 2 2 2 1 2 2 2 2 1 2 1 1 F 2 
99 108/09 CHELLAMUTHU 49 1 1 2 1 2 2 1 2 2 2 2 2 2 1 2 2 2 2 1 2 1 1 C 2 
100 312/09 MOHAN 56 1 1 2 2 2 2 1 2 2 2 2 2 2 1 2 2 2 2 1 1 1 1 A 1 
101 339/09 MURUGAN 65 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2 1 1 A 1 
102 428/09 VEERAMMAL 65 2 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2 1 1 C 2 
103 485/09 AMIRTHAMMAL 70 2 1 1 2 1 1 2 2 2 2 2 2 2 1 2 2 2 2 1 1 1 1 F 2 
104 63/09 KESAVAN 75 1 1 2 2 2 2 1 2 2 2 2 2 1 1 2 2 2 2 2 2 1 1 C 2 
105 61/09 SEETHALAKSHMI 28 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2 1 2 F 2 
106 86/09 SENTHILVELAN 38 1 2 1 1 2 2 1 2 2 2 2 2 2 1 2 2 2 2 1 1 1 2 A 1 
107 242/09 BAASHA 48 1 1 2 2 2 2 2 2 2 2 1 2 2 1 2 2 2 2 1 2 1 3 F 2 
108 179/09 MUNISAMY 54 1 1 2 2 2 1 2 2 2 2 2 2 2 1 2 2 2 2 1 2 1 2 F 2 
109 358/09 GANGAN 55 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 1 A 1 
110 656/09 MUNUSAMY 65 1 1 2 2 2 2 1 2 2 2 2 2 2 2 1 2 2 2 2 1 1 3 C 2 
111 435/09 VARADHAN 70 1 2 2 2 2 2 1 2 2 2 1 2 2 1 2 2 2 2 1 1 1 3 C 2 
112 711/09 SUMATHI 34 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 F 2 
113 861/09 PRABAKARAN 53 1 1 1 2 1 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2 1 1 C 2 
114 990/09 KUPPAMMAL 66 2 1 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 1 C 2 
115 1134/09 SUDALAIMANI 75 1 2 2 2 1 1 2 2 2 2 1 2 2 1 2 2 2 2 1 1 1 2 A 1 
116 1133/09 GOVINDARAJ 65 1 1 2 2 1 1 1 2 1 2 2 2 1 1 2 2 2 2 2 2 1 1 A 1 
117 1156/09 MANI 55 1 1 1 1 1 1 2 2 1 2 2 2 2 1 2 2 2 2 1 2 1 1 A 1 
118 747/09 RAJENDRAN 47 1 1 2 2 1 1 2 1 2 2 2 2 2 1 2 1 2 2 1 1 1 2 F 2 
119 912/09 SARADHA 48 2 1 2 1 2 2 2 1 1 2 2 2 2 1 2 1 2 2 1 2 1 1 A 1 
120 1154/09 DURAI 57 1 1 2 1 2 1 1 2 1 2 2 2 2 1 2 2 2 2 1 2 1 1 A 1 
121 1433/09 EASAKIYAL 60 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 1 1 2 F 2 
122 1537/09 CHOKKAMMAL 49 2 1 2 2 1 1 2 2 1 2 2 2 2 1 1 2 2 2 1 2 1 1 A 1 
123 1541/09 ANWAR BASHA 63 1 1 2 2 2 1 2 2 2 2 2 2 2 1 2 2 2 2 1 1 1 2 F 2 
124 1693/09 RAJI 47 1 2 2 2 2 1 2 1 2 2 2 2 2 2 2 1 2 2 2 1 2 2 F 2 
125 1749/09 PEETHAMBARAM 58 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 1 3 D 2 
126 1428/09 POONKODI 36 2 1 2 2 1 1 2 1 2 2 2 2 2 1 2 1 2 2 1 2 1 1 C 2 
127 1677/09 GOVINDAMMAL 60 2 2 1 2 1 1 2 2 2 2 1 2 2 1 2 2 2 2 1 1 1 4 E 2 
128 1924/09 PONNUSAMY 55 1 1 1 2 1 1 1 1 2 2 2 2 2 1 2 1 2 2 1 2 1 1 C 2 
129 2242/09 MADHAN 49 1 1 1 2 2 1 1 2 2 2 2 2 2 1 2 2 2 2 1 1 1 4 F 2 
130 2236/09 MUTHUKUMAR 60 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 1 1 2 F 2 
131 2225/09 SAVITHRI 45 2 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 A 1 
132 561/09 PRABHAKARAN 53 1 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 1 1 A 1 
133 2213/09 MUTHU 70 1 1 2 2 1 2 2 2 2 2 2 2 2 1 2 2 2 2 1 1 1 1 C 2 
134 2209/09 PATCHIAPPAN 60 1 2 2 2 1 1 2 2 2 1 2 2 2 2 2 2 2 1 2 2 2 1 B 2 
135 2257/09 MAGIMAIRAJ 74 1 2 2 2 1 1 2 2 2 2 1 2 1 1 2 2 1 2 1 1 1 3 E 2 
136 2525/09 PAULRAJ 72 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 1 A 1 
137 2532/09 BALARAMAN 65 1 2 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 1 2 C 2 
138 2699/09 KANDAMMAL 55 2 1 2 2 2 2 2 2 2 2 1 2 2 1 2 2 1 2 1 1 1 3 D 2 
139 4613/09 BABY 57 2 1 2 2 2 2 2 2 2 1 2 2 2 1 2 2 2 1 1 1 1 3 B 2 
140 4660/09 GEETHA 39 2 1 1 1 2 2 1 2 1 2 2 2 2 1 2 2 2 2 1 2 1 1 A 1 
141 4976/09 VARADHARAJAN 63 1 1 2 2 1 1 1 2 2 2 2 2 2 1 2 2 2 2 1 1 1 2 A 1 
142 4934/09 CHENNAMMAL 55 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 1 C 2 
143 5095/09 KRISHNAN 76 1 2 2 2 1 1 1 2 2 1 2 2 2 1 2 2 1 1 1 2 1 1 E 2 
144 5079/09 NARAYANAN 64 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2 1 2 F 2 
145 5168/09 RAJAMANI 68 1 2 2 2 2 2 2 2 2 2 1 2 2 1 2 2 2 2 1 1 1 3 D 2 
146 5258/09 PANCHATCHARAM 70 1 2 2 2 1 1 1 2 2 2 2 2 2 1 2 2 2 2 1 1 1 1 C 2 
147 5168/09 RAJAMANI 68 2 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 1 1 3 D 2 
148 5509/09 SUBRAMANI 43 1 2 2 2 2 2 1 2 2 2 2 2 1 1 2 2 2 2 1 2 1 1 A 1 
149 5598/09 VELU 66 1 1 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 1 2 1 A 1 
150 5666/09 BASKAR 46 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 1 4 D 2 
151 5798/09 ELUMALAI 57 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2 1 1 A 1 
152 5904/09 GANESAN 65 1 2 2 2 1 1 1 2 2 2 2 2 2 1 2 2 2 2 1 1 1 1 C 2 
153 5894/09 VARADHAN 58 1 1 1 1 2 1 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 1 A 1 
154 6151/09 NAGAMMAL 55 2 1 1 2 1 1 1 2 1 2 2 2 1 1 2 2 1 2 1 1 1 1 D 2 
155 6212/09 RAMALINGAM 61 1 1 2 2 1 1 1 2 2 2 2 2 2 1 2 2 2 2 1 1 1 1 F 2 
156 6268/09 KUMUDHAVALLI 67 2 1 1 1 1 1 1 2 1 2 2 2 2 1 2 2 2 2 1 2 1 1 A 1 
157 6994/09 SOORAN 55 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 F 2 
158 861/09 PRABAKARAN 53 1 1 1 1 2 2 2 2 2 2 2 2 2 1 1 2 2 2 1 1 1 1 C 2 
159 5491/09 ARUMUGAM 72 1 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 1 1 4 D 2 
160 5653/09 GANESAN 65 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 A 1 
161 5737/09 RANI 50 2 2 2 2 1 1 2 2 2 2 1 2 2 1 2 2 2 2 1 1 1 3 F 2 
162 5868/09 SABIYABEE 65 2 2 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2 1 1 C 2 
163 6036/09 AMBIKA 55 2 2 2 2 1 1 2 2 2 2 2 2 2 1 2 2 2 2 1 1 1 2 A 1 
164 5989/09 KANNIAMMAL 76 2 1 1 2 2 2 1 2 1 1 2 2 2 1 2 2 2 2 1 1 1 1 A 1 
165 6154/09 NATARAJ 47 1 1 2 2 1 1 1 2 2 2 2 2 1 1 2 2 2 2 1 2 1 2 F 2 
166 6799/09 BAKTHAN 60 1 1 2 2 1 2 2 2 2 2 1 2 2 1 2 2 2 2 1 1 1 3 A 1 
167 6884/09 SUBRAMANI 60 1 1 1 1 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 1 1 2 F 2 
168 6857/09 BALARAMAN 61 1 1 2 2 2 2 2 2 2 1 2 2 2 1 2 2 1 1 1 2 1 1 E 2 
169 6901/09 RAJARAM 57 1 1 2 2 2 2 2 2 2 2 2 2 2 1 1 2 2 2 1 2 1 1 C 2 
170 7110/09 SANKAR 40 1 1 2 2 2 1 1 2 1 2 2 2 2 2 2 2 2 2 2 1 1 1 A 1 
171 7227/09 ARUMUGAM 58 1 1 2 2 1 1 1 2 2 2 2 2 2 1 2 2 2 2 1 2 1 1 A 1 
172 7237/09 AYYANAR 41 1 1 2 2 2 2 1 1 1 2 2 2 2 2 2 1 2 2 2 1 1 1 F 2 
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CT scan abdomen – Growth stomach with gastric wall thickening 
 
         
Antral wall thickening with                      Growth stomach with multiple 
ascites                                                          liver secondaries 
 
 
 
 
a8 
 
 
OG Junction Growth 
 
Malignant Gastric Ulcer 
 
Antral growth 
 
         +----------------------------------+-----------+-----------+ 
         |                                  | Frequency |Percentage | 
         +----------------------------------+-----------+-----------+ 
         |Age Group                         |           |           | 
         |Below 40                          |      24   |    13.95  | 
         |41-50                             |      39   |    22.67  | 
         |51-60                             |      44   |    25.58  | 
         |Above 60                          |      65   |    37.79  | 
         +----------------------------------+-----------+-----------+ 
         |Total                             |     172   |   100.00  | 
         +----------------------------------+-----------+-----------+ 
 
       
 
 
         +----------------------------------+-----------+-----------+ 
         |                                  | Frequency |Percentage | 
         +----------------------------------+-----------+-----------+ 
         |Sex                               |           |           | 
         |Male                              |     123   |    71.51  | 
         |Female                            |      49   |    28.49  | 
         +----------------------------------+-----------+-----------+ 
         |Total                             |     172   |   100.00  | 
         +----------------------------------+-----------+-----------+ 
 
       
 
 
        +------------------------+-----------+-----------+-----------+ 
        |                        |    Yes    |    No     |   Total   | 
        |                        +-----+-----+-----+-----+-----+-----+ 
        |                        |Count|  %  |Count|  %  |Count|  %  | 
        +------------------------+-----+-----+-----+-----+-----+-----+ 
        |PC1                     |  105|61.05|   67|38.95|  172|100.0| 
        |PC2                     |   67|38.95|  105|61.05|  172|100.0| 
        |PC3                     |   32|18.60|  140|81.40|  172|100.0| 
        |PC4                     |   67|38.95|  105|61.05|  172|100.0| 
        |PC5                     |   79|45.93|   93|54.07|  172|100.0| 
        |PC6                     |   66|38.37|  106|61.63|  172|100.0| 
        |PC7                     |   19|11.05|  153|88.95|  172|100.0| 
        |PC8                     |   31|18.02|  141|81.98|  172|100.0| 
        |PC9                     |   15| 8.72|  157|91.28|  172|100.0| 
        |PC10                    |   22|12.79|  150|87.21|  172|100.0| 
        |PC11                    |    1|  .58|  171|99.42|  172|100.0| 
        |PC12                    |   13| 7.56|  159|92.44|  172|100.0| 
        |PC13                    |     |     |     |     |     |     | 
        +------------------------+-----+-----+-----+-----+-----+-----+ 
 
       
 
 
        +------------------------+-----------+-----------+-----------+ 
        |                        |    Yes    |    No     |   Total   | 
        |                        +-----+-----+-----+-----+-----+-----+ 
        |                        |Count|  %  |Count|  %  |Count|  %  | 
        +------------------------+-----+-----+-----+-----+-----+-----+ 
        |RF1                     |   12| 6.98|  160|93.02|  172|100.0| 
        |RF2                     |     |     |     |     |     |     | 
        |RF3                     |     |     |     |     |     |     | 
        |RF4                     |  106|61.63|   66|38.37|  172|100.0| 
        |RF5                     |   80|46.51|   92|53.49|  172|100.0| 
        |RF6                     |     |     |     |     |     |     | 
        |RF7                     |  123|71.51|   49|28.49|  172|100.0| 
        |RF8                     |  123|71.51|   49|28.49|  172|100.0| 
        +------------------------+-----+-----+-----+-----+-----+-----+ 
 
       
 
 
        +------------------------+-----------+-----------+-----------+ 
        |                        |    Yes    |    No     |   Total   | 
        |                        +-----+-----+-----+-----+-----+-----+ 
        |                        |Count|  %  |Count|  %  |Count|  %  | 
        +------------------------+-----+-----+-----+-----+-----+-----+ 
        |PF1                     |  123|71.51|   49|28.49|  172|100.0| 
        |PF2                     |    1|  .58|  171|99.42|  172|100.0| 
        |PF3                     |     |     |  172|100.0|  172|100.0| 
        |PF4                     |     |     |     |     |     |     | 
        |PF5                     |   12| 6.98|  160|93.02|  172|100.0| 
        |PF6                     |     |     |     |     |     |     | 
        |PF7                     |   19|11.05|  153|88.95|  172|100.0| 
        |PF8                     |   11| 6.40|  161|93.60|  172|100.0| 
        |PF9                     |   14| 8.14|  158|91.86|  172|100.0| 
        |PF10                    |     |     |     |     |     |     | 
        +------------------------+-----+-----+-----+-----+-----+-----+ 
 
       
 
 
         +----------------------------------+-----------+-----------+ 
         |                                  | Frequency |Percentage | 
         +----------------------------------+-----------+-----------+ 
         |HB                                |           |           | 
         |<= 9                              |     113   |    65.70  | 
         |> 9                               |      59   |    34.30  | 
         +----------------------------------+-----------+-----------+ 
         |Total                             |     172   |   100.00  | 
         +----------------------------------+-----------+-----------+ 
         |Blood Group                       |           |           | 
         |A                                 |      96   |    55.81  | 
         |Others                            |      76   |    44.19  | 
         +----------------------------------+-----------+-----------+ 
         |Total                             |     172   |   100.00  | 
         +----------------------------------+-----------+-----------+ 
 
       
 
 
         +----------------------------------+-----------+-----------+ 
         |                                  | Frequency |Percentage | 
         +----------------------------------+-----------+-----------+ 
         |ESR                               |           |           | 
         |>= 30                             |     134   |    77.91  | 
         |< 30                              |      38   |    22.09  | 
         +----------------------------------+-----------+-----------+ 
         |Total                             |     172   |   100.00  | 
         +----------------------------------+-----------+-----------+ 
 
       
 
 
         +----------------------------------+-----------+-----------+ 
         |                                  | Frequency |Percentage | 
         +----------------------------------+-----------+-----------+ 
         |VOGD                              |           |           | 
         |Antral growth                     |      94   |    54.65  | 
         |Mid Body growth                   |      38   |    22.09  | 
         |OG Junction growth                |      26   |    15.12  | 
         |Diffuse gastric growth            |      14   |     8.14  | 
         +----------------------------------+-----------+-----------+ 
         |Total                             |     172   |   100.00  | 
         +----------------------------------+-----------+-----------+ 
         |GOO                               |           |           | 
         |Yes                               |      56   |    58.33  | 
         |No                                |      40   |    41.67  | 
         +----------------------------------+-----------+-----------+ 
         |Total                             |      96   |   100.00  | 
         +----------------------------------+-----------+-----------+ 
 
       
 
 
         +----------------------------------+-----------+-----------+ 
         |                                  | Frequency |Percentage | 
         +----------------------------------+-----------+-----------+ 
         |CT scan                           |           |           | 
         |Normal                            |      62   |    36.05  | 
         |Ascites                           |       6   |     3.49  | 
         |Nodes                             |      42   |    24.42  | 
         |Liver Secondary                   |      10   |     5.81  | 
         |Nodes + Secondary/Ascites         |       7   |     4.07  | 
         |T4 lesion                         |      45   |    26.16  | 
         +----------------------------------+-----------+-----------+ 
         |Total                             |     172   |   100.00  | 
         +----------------------------------+-----------+-----------+ 
         |Treatment                         |           |           | 
         |Curative                          |      62   |    36.05  | 
         |Paliative                         |     110   |    63.95  | 
         +----------------------------------+-----------+-----------+ 
         |Total                             |     172   |   100.00  | 
         +----------------------------------+-----------+-----------+ 
 
 
 
                                                   Valid 
Variable      Mean    Std Dev   Minimum   Maximum      N  Label 
 
AGE          55.76      11.34        28        77    172 
 
       
 
PC1  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
PC1        --------+--------+--------+--------+--------+ 
                1  |    65  |    19  |    13  |     8  |   105 
  Yes              |  61.9  |  18.1  |  12.4  |   7.6  |  61.0 
                   |  69.1  |  50.0  |  50.0  |  57.1  | 
                   +--------+--------+--------+--------+ 
                2  |    29  |    19  |    13  |     6  |    67 
  No               |  43.3  |  28.4  |  19.4  |   9.0  |  39.0 
                   |  30.9  |  50.0  |  50.0  |  42.9  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                          5.96894           3                  .11313 
Likelihood Ratio                 5.96743           3                  .11321 
Mantel-Haenszel test for         3.36397           1                  .06664 
      linear association 
 
Minimum Expected Frequency -    5.453 
 
 
 
Number of Missing Observations:  0 
 
 
PC2  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
PC2        --------+--------+--------+--------+--------+ 
                1  |    43  |     6  |     4  |    14  |    67 
  Yes              |  64.2  |   9.0  |   6.0  |  20.9  |  39.0 
                   |  45.7  |  15.8  |  15.4  | 100.0  | 
                   +--------+--------+--------+--------+ 
                2  |    51  |    32  |    22  |        |   105 
  No               |  48.6  |  30.5  |  21.0  |        |  61.0 
                   |  54.3  |  84.2  |  84.6  |        | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                         38.41138           3                  .00000 
Likelihood Ratio                44.87449           3                  .00000 
Mantel-Haenszel test for          .52641           1                  .46812 
      linear association 
 
Minimum Expected Frequency -    5.453 
 
 
 
Number of Missing Observations:  0 
 
 
PC3  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
PC3        --------+--------+--------+--------+--------+ 
                1  |    23  |     5  |     2  |     2  |    32 
  Yes              |  71.9  |  15.6  |   6.3  |   6.3  |  18.6 
                   |  24.5  |  13.2  |   7.7  |  14.3  | 
                   +--------+--------+--------+--------+ 
                2  |    71  |    33  |    24  |    12  |   140 
  No               |  50.7  |  23.6  |  17.1  |   8.6  |  81.4 
                   |  75.5  |  86.8  |  92.3  |  85.7  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                          5.09549           3                  .16494 
Likelihood Ratio                 5.48721           3                  .13941 
Mantel-Haenszel test for         3.59802           1                  .05785 
      linear association 
 
Minimum Expected Frequency -    2.605 
Cells with Expected Frequency < 5 -     2 OF     8 ( 25.0%) 
 
 
 
Number of Missing Observations:  0 
 
 
PC4  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
PC4        --------+--------+--------+--------+--------+ 
                1  |    37  |    15  |    12  |     3  |    67 
  Yes              |  55.2  |  22.4  |  17.9  |   4.5  |  39.0 
                   |  39.4  |  39.5  |  46.2  |  21.4  | 
                   +--------+--------+--------+--------+ 
                2  |    57  |    23  |    14  |    11  |   105 
  No               |  54.3  |  21.9  |  13.3  |  10.5  |  61.0 
                   |  60.6  |  60.5  |  53.8  |  78.6  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                          2.38591           3                  .49626 
Likelihood Ratio                 2.53377           3                  .46922 
Mantel-Haenszel test for          .29311           1                  .58824 
      linear association 
 
Minimum Expected Frequency -    5.453 
 
 
 
Number of Missing Observations:  0 
 
 
PC5  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
PC5        --------+--------+--------+--------+--------+ 
                1  |    45  |    18  |    11  |     5  |    79 
  Yes              |  57.0  |  22.8  |  13.9  |   6.3  |  45.9 
                   |  47.9  |  47.4  |  42.3  |  35.7  | 
                   +--------+--------+--------+--------+ 
                2  |    49  |    20  |    15  |     9  |    93 
  No               |  52.7  |  21.5  |  16.1  |   9.7  |  54.1 
                   |  52.1  |  52.6  |  57.7  |  64.3  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                           .90015           3                  .82539 
Likelihood Ratio                  .91155           3                  .82264 
Mantel-Haenszel test for          .76064           1                  .38313 
      linear association 
 
Minimum Expected Frequency -    6.430 
 
 
 
Number of Missing Observations:  0 
 
 
PC6  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
PC6        --------+--------+--------+--------+--------+ 
                1  |    42  |     8  |     9  |     7  |    66 
  Yes              |  63.6  |  12.1  |  13.6  |  10.6  |  38.4 
                   |  44.7  |  21.1  |  34.6  |  50.0  | 
                   +--------+--------+--------+--------+ 
                2  |    52  |    30  |    17  |     7  |   106 
  No               |  49.1  |  28.3  |  16.0  |   6.6  |  61.6 
                   |  55.3  |  78.9  |  65.4  |  50.0  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                          7.35782           3                  .06133 
Likelihood Ratio                 7.74528           3                  .05158 
Mantel-Haenszel test for          .33621           1                  .56203 
      linear association 
 
Minimum Expected Frequency -    5.372 
 
 
 
Number of Missing Observations:  0 
 
 
PC7  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
PC7        --------+--------+--------+--------+--------+ 
                1  |    11  |     5  |     2  |     1  |    19 
  Yes              |  57.9  |  26.3  |  10.5  |   5.3  |  11.0 
                   |  11.7  |  13.2  |   7.7  |   7.1  | 
                   +--------+--------+--------+--------+ 
                2  |    83  |    33  |    24  |    13  |   153 
  No               |  54.2  |  21.6  |  15.7  |   8.5  |  89.0 
                   |  88.3  |  86.8  |  92.3  |  92.9  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                           .72832           3                  .86652 
Likelihood Ratio                  .77779           3                  .85477 
Mantel-Haenszel test for          .40444           1                  .52480 
      linear association 
 
Minimum Expected Frequency -    1.547 
Cells with Expected Frequency < 5 -     3 OF     8 ( 37.5%) 
 
 
 
Number of Missing Observations:  0 
 
 
PC8  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
PC8        --------+--------+--------+--------+--------+ 
                1  |    23  |     3  |     2  |     3  |    31 
  Yes              |  74.2  |   9.7  |   6.5  |   9.7  |  18.0 
                   |  24.5  |   7.9  |   7.7  |  21.4  | 
                   +--------+--------+--------+--------+ 
                2  |    71  |    35  |    24  |    11  |   141 
  No               |  50.4  |  24.8  |  17.0  |   7.8  |  82.0 
                   |  75.5  |  92.1  |  92.3  |  78.6  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                          7.26907           3                  .06380 
Likelihood Ratio                 8.03387           3                  .04532 
Mantel-Haenszel test for         2.45000           1                  .11752 
      linear association 
 
Minimum Expected Frequency -    2.523 
Cells with Expected Frequency < 5 -     2 OF     8 ( 25.0%) 
 
 
 
Number of Missing Observations:  0 
 
 
PC9  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
PC9        --------+--------+--------+--------+--------+ 
                1  |     9  |     1  |     1  |     4  |    15 
  Yes              |  60.0  |   6.7  |   6.7  |  26.7  |   8.7 
                   |   9.6  |   2.6  |   3.8  |  28.6  | 
                   +--------+--------+--------+--------+ 
                2  |    85  |    37  |    25  |    10  |   157 
  No               |  54.1  |  23.6  |  15.9  |   6.4  |  91.3 
                   |  90.4  |  97.4  |  96.2  |  71.4  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                          9.56232           3                  .02268 
Likelihood Ratio                 8.01935           3                  .04561 
Mantel-Haenszel test for          .91170           1                  .33967 
      linear association 
 
Minimum Expected Frequency -    1.221 
Cells with Expected Frequency < 5 -     3 OF     8 ( 37.5%) 
 
 
 
Number of Missing Observations:  0 
 
 
PC10  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
PC10       --------+--------+--------+--------+--------+ 
                1  |     2  |     2  |    16  |     2  |    22 
  Yes              |   9.1  |   9.1  |  72.7  |   9.1  |  12.8 
                   |   2.1  |   5.3  |  61.5  |  14.3  | 
                   +--------+--------+--------+--------+ 
                2  |    92  |    36  |    10  |    12  |   150 
  No               |  61.3  |  24.0  |   6.7  |   8.0  |  87.2 
                   |  97.9  |  94.7  |  38.5  |  85.7  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                         66.92915           3                  .00000 
Likelihood Ratio                50.38358           3                  .00000 
Mantel-Haenszel test for        28.57044           1                  .00000 
      linear association 
 
Minimum Expected Frequency -    1.791 
Cells with Expected Frequency < 5 -     3 OF     8 ( 37.5%) 
 
 
 
 
Number of Missing Observations:  0 
 
 
PC11  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
PC11       --------+--------+--------+--------+--------+ 
                1  |     1  |        |        |        |     1 
  Yes              | 100.0  |        |        |        |    .6 
                   |   1.1  |        |        |        | 
                   +--------+--------+--------+--------+ 
                2  |    93  |    38  |    26  |    14  |   171 
  No               |  54.4  |  22.2  |  15.2  |   8.2  |  99.4 
                   |  98.9  | 100.0  | 100.0  | 100.0  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                           .83464           3                  .84117 
Likelihood Ratio                 1.21325           3                  .74983 
Mantel-Haenszel test for          .60770           1                  .43566 
      linear association 
 
Minimum Expected Frequency -     .081 
Cells with Expected Frequency < 5 -     4 OF     8 ( 50.0%) 
 
 
 
Number of Missing Observations:  0 
 
 
PC12  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
PC12       --------+--------+--------+--------+--------+ 
                1  |     9  |     2  |     1  |     1  |    13 
  Yes              |  69.2  |  15.4  |   7.7  |   7.7  |   7.6 
                   |   9.6  |   5.3  |   3.8  |   7.1  | 
                   +--------+--------+--------+--------+ 
                2  |    85  |    36  |    25  |    13  |   159 
  No               |  53.5  |  22.6  |  15.7  |   8.2  |  92.4 
                   |  90.4  |  94.7  |  96.2  |  92.9  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                          1.34963           3                  .71738 
       
 
RF1  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
RF1        --------+--------+--------+--------+--------+ 
                1  |     9  |     1  |     1  |     1  |    12 
  Yes              |  75.0  |   8.3  |   8.3  |   8.3  |   7.0 
                   |   9.6  |   2.6  |   3.8  |   7.1  | 
                   +--------+--------+--------+--------+ 
                2  |    85  |    37  |    25  |    13  |   160 
  No               |  53.1  |  23.1  |  15.6  |   8.1  |  93.0 
                   |  90.4  |  97.4  |  96.2  |  92.9  | 
 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                          2.47610           3                  .47963 
Likelihood Ratio                 2.77528           3                  .42758 
Mantel-Haenszel test for          .94649           1                  .33062 
      linear association 
 
Minimum Expected Frequency -     .977 
Cells with Expected Frequency < 5 -     3 OF     8 ( 37.5%) 
 
 
 
Number of Missing Observations:  0 
 
 
>Warning # 10370 
>The crosstabulation table is empty. 
>It is a 2-way table for the variables: 
>RF2 by VOGD 
 
 
>Warning # 10370 
>The crosstabulation table is empty. 
>It is a 2-way table for the variables: 
>RF3 by VOGD 
 
 
RF4  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
RF4        --------+--------+--------+--------+--------+ 
                1  |    60  |    23  |    16  |     7  |   106 
  Yes              |  56.6  |  21.7  |  15.1  |   6.6  |  61.6 
                   |  63.8  |  60.5  |  61.5  |  50.0  | 
                   +--------+--------+--------+--------+ 
                2  |    34  |    15  |    10  |     7  |    66 
  No               |  51.5  |  22.7  |  15.2  |  10.6  |  38.4 
                   |  36.2  |  39.5  |  38.5  |  50.0  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                          1.01276           3                  .79816 
Likelihood Ratio                  .99212           3                  .80316 
Mantel-Haenszel test for          .72155           1                  .39564 
      linear association 
 
Minimum Expected Frequency -    5.372 
 
 
 
Number of Missing Observations:  0 
 
 
RF5  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
RF5        --------+--------+--------+--------+--------+ 
                1  |    46  |    16  |    12  |     6  |    80 
  Yes              |  57.5  |  20.0  |  15.0  |   7.5  |  46.5 
                   |  48.9  |  42.1  |  46.2  |  42.9  | 
                   +--------+--------+--------+--------+ 
                2  |    48  |    22  |    14  |     8  |    92 
  No               |  52.2  |  23.9  |  15.2  |   8.7  |  53.5 
                   |  51.1  |  57.9  |  53.8  |  57.1  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                           .59517           3                  .89754 
Likelihood Ratio                  .59670           3                  .89719 
Mantel-Haenszel test for          .27637           1                  .59909 
      linear association 
 
Minimum Expected Frequency -    6.512 
 
 
 
Number of Missing Observations:  0 
 
 
>Warning # 10370 
>The crosstabulation table is empty. 
>It is a 2-way table for the variables: 
>RF6 by VOGD 
 
 
RF7  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
RF7        --------+--------+--------+--------+--------+ 
                1  |    66  |    28  |    19  |    10  |   123 
  Yes              |  53.7  |  22.8  |  15.4  |   8.1  |  71.5 
                   |  70.2  |  73.7  |  73.1  |  71.4  | 
                   +--------+--------+--------+--------+ 
                2  |    28  |    10  |     7  |     4  |    49 
  No               |  57.1  |  20.4  |  14.3  |   8.2  |  28.5 
                   |  29.8  |  26.3  |  26.9  |  28.6  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                           .19720           3                  .97804 
Likelihood Ratio                  .19828           3                  .97787 
Mantel-Haenszel test for          .07538           1                  .78366 
      linear association 
 
Minimum Expected Frequency -    3.988 
Cells with Expected Frequency < 5 -     1 OF     8 ( 12.5%) 
 
 
 
Number of Missing Observations:  0 
 
 
RF8  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
RF8        --------+--------+--------+--------+--------+ 
                1  |    66  |    28  |    19  |    10  |   123 
  Yes              |  53.7  |  22.8  |  15.4  |   8.1  |  71.5 
                   |  70.2  |  73.7  |  73.1  |  71.4  | 
                   +--------+--------+--------+--------+ 
                2  |    28  |    10  |     7  |     4  |    49 
  No               |  57.1  |  20.4  |  14.3  |   8.2  |  28.5 
                   |  29.8  |  26.3  |  26.9  |  28.6  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                           .19720           3                  .97804 
Likelihood Ratio                  .19828           3                  .97787 
Mantel-Haenszel test for          .07538           1                  .78366 
      linear association 
 
Minimum Expected Frequency -    3.988 
Cells with Expected Frequency < 5 -     1 OF     8 ( 12.5%) 
 
 
 
Number of Missing Observations:  0 
 
 
PF1  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
PF1        --------+--------+--------+--------+--------+ 
                1  |    66  |    28  |    19  |    10  |   123 
  Yes              |  53.7  |  22.8  |  15.4  |   8.1  |  71.5 
                   |  70.2  |  73.7  |  73.1  |  71.4  | 
                   +--------+--------+--------+--------+ 
                2  |    28  |    10  |     7  |     4  |    49 
  No               |  57.1  |  20.4  |  14.3  |   8.2  |  28.5 
                   |  29.8  |  26.3  |  26.9  |  28.6  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
 
--------------------          -----------        ----              ------------ 
 
Pearson                           .19720           3                  .97804 
Likelihood Ratio                  .19828           3                  .97787 
Mantel-Haenszel test for          .07538           1                  .78366 
      linear association 
 
Minimum Expected Frequency -    3.988 
Cells with Expected Frequency < 5 -     1 OF     8 ( 12.5%) 
 
 
 
Number of Missing Observations:  0 
 
 
PF2  by  VOGD  VOGD 
 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
PF2        --------+--------+--------+--------+--------+ 
                1  |     1  |        |        |        |     1 
  Yes              | 100.0  |        |        |        |    .6 
                   |   1.1  |        |        |        | 
                   +--------+--------+--------+--------+ 
                2  |    93  |    38  |    26  |    14  |   171 
  No               |  54.4  |  22.2  |  15.2  |   8.2  |  99.4 
                   |  98.9  | 100.0  | 100.0  | 100.0  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                           .83464           3                  .84117 
Likelihood Ratio                 1.21325           3                  .74983 
Mantel-Haenszel test for          .60770           1                  .43566 
      linear association 
 
Minimum Expected Frequency -     .081 
Cells with Expected Frequency < 5 -     4 OF     8 ( 50.0%) 
 
 
 
Number of Missing Observations:  0 
 
 
PF3  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
PF3        --------+--------+--------+--------+--------+ 
                2  |    94  |    38  |    26  |    14  |   172 
  No               |  54.7  |  22.1  |  15.1  |   8.1  | 100.0 
                   | 100.0  | 100.0  | 100.0  | 100.0  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
>Warning # 10307 
>Statistics cannot be computed when the number of non-empty rows or columns 
>is one. 
 
 
Number of Missing Observations:  0 
 
 
>Warning # 10370 
>The crosstabulation table is empty. 
>It is a 2-way table for the variables: 
>PF4 by VOGD 
 
 
PF5  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
PF5        --------+--------+--------+--------+--------+ 
                1  |     9  |     1  |     1  |     1  |    12 
  Yes              |  75.0  |   8.3  |   8.3  |   8.3  |   7.0 
                   |   9.6  |   2.6  |   3.8  |   7.1  | 
                   +--------+--------+--------+--------+ 
                2  |    85  |    37  |    25  |    13  |   160 
  No               |  53.1  |  23.1  |  15.6  |   8.1  |  93.0 
                   |  90.4  |  97.4  |  96.2  |  92.9  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                          2.47610           3                  .47963 
Likelihood Ratio                 2.77528           3                  .42758 
Mantel-Haenszel test for          .94649           1                  .33062 
      linear association 
 
Minimum Expected Frequency -     .977 
Cells with Expected Frequency < 5 -     3 OF     8 ( 37.5%) 
 
 
 
Number of Missing Observations:  0 
 
 
>Warning # 10370 
>The crosstabulation table is empty. 
>It is a 2-way table for the variables: 
>PF6 by VOGD 
 
 
PF7  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
PF7        --------+--------+--------+--------+--------+ 
                1  |    11  |     5  |     2  |     1  |    19 
  Yes              |  57.9  |  26.3  |  10.5  |   5.3  |  11.0 
                   |  11.7  |  13.2  |   7.7  |   7.1  | 
                   +--------+--------+--------+--------+ 
                2  |    83  |    33  |    24  |    13  |   153 
  No               |  54.2  |  21.6  |  15.7  |   8.5  |  89.0 
                   |  88.3  |  86.8  |  92.3  |  92.9  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                           .72832           3                  .86652 
Likelihood Ratio                  .77779           3                  .85477 
Mantel-Haenszel test for          .40444           1                  .52480 
      linear association 
 
Minimum Expected Frequency -    1.547 
Cells with Expected Frequency < 5 -     3 OF     8 ( 37.5%) 
 
 
 
Number of Missing Observations:  0 
 
 
PF8  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
PF8        --------+--------+--------+--------+--------+ 
                1  |     6  |        |     5  |        |    11 
  Yes              |  54.5  |        |  45.5  |        |   6.4 
                   |   6.4  |        |  19.2  |        | 
                   +--------+--------+--------+--------+ 
                2  |    88  |    38  |    21  |    14  |   161 
  No               |  54.7  |  23.6  |  13.0  |   8.7  |  93.6 
                   |  93.6  | 100.0  |  80.8  | 100.0  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                         10.70819           3                  .01341 
 
Likelihood Ratio                11.68847           3                  .00853 
Mantel-Haenszel test for          .24187           1                  .62286 
      linear association 
 
Minimum Expected Frequency -     .895 
Cells with Expected Frequency < 5 -     3 OF     8 ( 37.5%) 
 
 
 
Number of Missing Observations:  0 
 
 
PF9  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
PF9        --------+--------+--------+--------+--------+ 
                1  |     8  |     1  |     1  |     4  |    14 
  Yes              |  57.1  |   7.1  |   7.1  |  28.6  |   8.1 
                   |   8.5  |   2.6  |   3.8  |  28.6  | 
                   +--------+--------+--------+--------+ 
                2  |    86  |    37  |    25  |    10  |   158 
  No               |  54.4  |  23.4  |  15.8  |   6.3  |  91.9 
                   |  91.5  |  97.4  |  96.2  |  71.4  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                         10.01671           3                  .01842 
Likelihood Ratio                 7.86645           3                  .04885 
Mantel-Haenszel test for         1.44469           1                  .22938 
      linear association 
 
Minimum Expected Frequency -    1.140 
Cells with Expected Frequency < 5 -     3 OF     8 ( 37.5%) 
 
 
 
Number of Missing Observations:  0 
 
 
>Warning # 10370 
>The crosstabulation table is empty. 
>It is a 2-way table for the variables: 
>PF10 by VOGD 
 
       
 
BLO_GRP  Blood Group  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
BLO_GRP    --------+--------+--------+--------+--------+ 
                1  |    36  |    21  |    25  |    14  |    96 
  A                |  37.5  |  21.9  |  26.0  |  14.6  |  55.8 
                   |  38.3  |  55.3  |  96.2  | 100.0  | 
                   +--------+--------+--------+--------+ 
                2  |    58  |    17  |     1  |        |    76 
  Others           |  76.3  |  22.4  |   1.3  |        |  44.2 
                   |  61.7  |  44.7  |   3.8  |        | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                         39.93825           3                  .00000 
Likelihood Ratio                50.26253           3                  .00000 
Mantel-Haenszel test for        37.39904           1                  .00000 
      linear association 
 
Minimum Expected Frequency -    6.186 
 
 
 
Number of Missing Observations:  0 
 
 
ESR  ESR  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
ESR        --------+--------+--------+--------+--------+ 
                1  |    73  |    29  |    21  |    11  |   134 
  >= 30            |  54.5  |  21.6  |  15.7  |   8.2  |  77.9 
                   |  77.7  |  76.3  |  80.8  |  78.6  | 
                   +--------+--------+--------+--------+ 
                2  |    21  |     9  |     5  |     3  |    38 
  < 30             |  55.3  |  23.7  |  13.2  |   7.9  |  22.1 
                   |  22.3  |  23.7  |  19.2  |  21.4  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                           .18659           3                  .97973 
Likelihood Ratio                  .18981           3                  .97922 
Mantel-Haenszel test for          .04685           1                  .82864 
      linear association 
 
Minimum Expected Frequency -    3.093 
Cells with Expected Frequency < 5 -     1 OF     8 ( 12.5%) 
 
 
 
Number of Missing Observations:  0 
 
 
HB  HB  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
HB         --------+--------+--------+--------+--------+ 
                1  |    61  |    26  |    18  |     8  |   113 
  <= 9             |  54.0  |  23.0  |  15.9  |   7.1  |  65.7 
                   |  64.9  |  68.4  |  69.2  |  57.1  | 
                   +--------+--------+--------+--------+ 
 
                2  |    33  |    12  |     8  |     6  |    59 
  > 9              |  55.9  |  20.3  |  13.6  |  10.2  |  34.3 
                   |  35.1  |  31.6  |  30.8  |  42.9  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                           .75069           3                  .86122 
       
 
TREAT  Treatment  by  VOGD  VOGD 
 
                    VOGD                           Page 1 of 1 
            Count  | 
           Row Pct |Antral g Mid Body OG Junct Diffuse 
           Col Pct |rowth     growth  ion grow gastric    Row 
                   |       1|       2|       3|       4| Total 
TREAT      --------+--------+--------+--------+--------+ 
                1  |    46  |    10  |     5  |     1  |    62 
  Curative         |  74.2  |  16.1  |   8.1  |   1.6  |  36.0 
                   |  48.9  |  26.3  |  19.2  |   7.1  | 
                   +--------+--------+--------+--------+ 
                2  |    48  |    28  |    21  |    13  |   110 
  Paliative        |  43.6  |  25.5  |  19.1  |  11.8  |  64.0 
                   |  51.1  |  73.7  |  80.8  |  92.9  | 
                   +--------+--------+--------+--------+ 
            Column      94       38       26       14      172 
             Total    54.7     22.1     15.1      8.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                         16.59804           3                  .00086 
       
 
       
 
CT_SCAN  CT scan  by  TREAT  Treatment 
 
                    TREAT        Page 1 of 1 
            Count  | 
           Row Pct |Curative Paliativ 
           Col Pct |         e          Row 
                   |       1|       2| Total 
CT_SCAN    --------+--------+--------+ 
                1  |    61  |     1  |    62 
  Normal           |  98.4  |   1.6  |  36.0 
                   |  98.4  |    .9  | 
                   +--------+--------+ 
                2  |        |     6  |     6 
  Ascites          |        | 100.0  |   3.5 
                   |        |   5.5  | 
                   +--------+--------+ 
                3  |     1  |    41  |    42 
  Nodes            |   2.4  |  97.6  |  24.4 
                   |   1.6  |  37.3  | 
                   +--------+--------+ 
                4  |        |    10  |    10 
  Liver Secondary  |        | 100.0  |   5.8 
                   |        |   9.1  | 
                   +--------+--------+ 
                5  |        |     7  |     7 
  Nodes + Secondar |        | 100.0  |   4.1 
                   |        |   6.4  | 
                   +--------+--------+ 
                6  |        |    45  |    45 
  T4 lesion        |        | 100.0  |  26.2 
                   |        |  40.9  | 
                   +--------+--------+ 
            Column      62      110      172 
             Total    36.0     64.0    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                        163.49759           5                  .00000 
       
 
PC1  by  TREAT  Treatment 
 
                    TREAT        Page 1 of 1 
            Count  | 
           Row Pct |Curative Paliativ 
           Col Pct |         e          Row 
                   |       1|       2| Total 
PC1        --------+--------+--------+ 
                1  |    39  |    66  |   105 
 
  Yes              |  37.1  |  62.9  |  61.0 
                   |  62.9  |  60.0  | 
                   +--------+--------+ 
                2  |    23  |    44  |    67 
  No               |  34.3  |  65.7  |  39.0 
                   |  37.1  |  40.0  | 
                   +--------+--------+ 
            Column      62      110      172 
             Total    36.0     64.0    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                           .14054           1                  .70774 
Continuity Correction             .04497           1                  .83206 
Likelihood Ratio                  .14093           1                  .70736 
Mantel-Haenszel test for          .13973           1                  .70855 
      linear association 
 
Minimum Expected Frequency -   24.151 
 
 
 
Number of Missing Observations:  0 
 
 
PC2  by  TREAT  Treatment 
 
                    TREAT        Page 1 of 1 
            Count  | 
           Row Pct |Curative Paliativ 
           Col Pct |         e          Row 
                   |       1|       2| Total 
PC2        --------+--------+--------+ 
                1  |    22  |    45  |    67 
  Yes              |  32.8  |  67.2  |  39.0 
                   |  35.5  |  40.9  | 
                   +--------+--------+ 
                2  |    40  |    65  |   105 
  No               |  38.1  |  61.9  |  61.0 
                   |  64.5  |  59.1  | 
                   +--------+--------+ 
            Column      62      110      172 
             Total    36.0     64.0    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                           .49078           1                  .48358 
Continuity Correction             .28915           1                  .59077 
Likelihood Ratio                  .49346           1                  .48239 
Mantel-Haenszel test for          .48792           1                  .48486 
      linear association 
 
Minimum Expected Frequency -   24.151 
 
 
 
Number of Missing Observations:  0 
 
 
PC3  by  TREAT  Treatment 
 
 
                    TREAT        Page 1 of 1 
            Count  | 
           Row Pct |Curative Paliativ 
           Col Pct |         e          Row 
                   |       1|       2| Total 
PC3        --------+--------+--------+ 
                1  |    20  |    12  |    32 
  Yes              |  62.5  |  37.5  |  18.6 
                   |  32.3  |  10.9  | 
                   +--------+--------+ 
                2  |    42  |    98  |   140 
  No               |  30.0  |  70.0  |  81.4 
                   |  67.7  |  89.1  | 
                   +--------+--------+ 
            Column      62      110      172 
             Total    36.0     64.0    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                         11.93408           1                  .00055 
Continuity Correction           10.56592           1                  .00115 
Likelihood Ratio                11.48570           1                  .00070 
Mantel-Haenszel test for        11.86469           1                  .00057 
      linear association 
 
Minimum Expected Frequency -   11.535 
 
 
 
Number of Missing Observations:  0 
 
 
PC4  by  TREAT  Treatment 
 
                    TREAT        Page 1 of 1 
            Count  | 
           Row Pct |Curative Paliativ 
           Col Pct |         e          Row 
                   |       1|       2| Total 
PC4        --------+--------+--------+ 
                1  |    26  |    41  |    67 
  Yes              |  38.8  |  61.2  |  39.0 
                   |  41.9  |  37.3  | 
                   +--------+--------+ 
                2  |    36  |    69  |   105 
  No               |  34.3  |  65.7  |  61.0 
                   |  58.1  |  62.7  | 
                   +--------+--------+ 
            Column      62      110      172 
             Total    36.0     64.0    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                           .36252           1                  .54711 
Continuity Correction             .19295           1                  .66047 
Likelihood Ratio                  .36126           1                  .54781 
Mantel-Haenszel test for          .36041           1                  .54828 
      linear association 
 
Minimum Expected Frequency -   24.151 
 
 
 
Number of Missing Observations:  0 
 
 
PC5  by  TREAT  Treatment 
 
                    TREAT        Page 1 of 1 
            Count  | 
           Row Pct |Curative Paliativ 
           Col Pct |         e          Row 
                   |       1|       2| Total 
PC5        --------+--------+--------+ 
                1  |    30  |    49  |    79 
  Yes              |  38.0  |  62.0  |  45.9 
                   |  48.4  |  44.5  | 
                   +--------+--------+ 
                2  |    32  |    61  |    93 
  No               |  34.4  |  65.6  |  54.1 
                   |  51.6  |  55.5  | 
                   +--------+--------+ 
            Column      62      110      172 
             Total    36.0     64.0    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                           .23563           1                  .62738 
Continuity Correction             .10633           1                  .74436 
 
Likelihood Ratio                  .23543           1                  .62753 
Mantel-Haenszel test for          .23426           1                  .62838 
      linear association 
 
Minimum Expected Frequency -   28.477 
 
 
 
Number of Missing Observations:  0 
 
 
PC6  by  TREAT  Treatment 
 
                    TREAT        Page 1 of 1 
            Count  | 
           Row Pct |Curative Paliativ 
           Col Pct |         e          Row 
                   |       1|       2| Total 
PC6        --------+--------+--------+ 
                1  |    30  |    36  |    66 
  Yes              |  45.5  |  54.5  |  38.4 
                   |  48.4  |  32.7  | 
                   +--------+--------+ 
                2  |    32  |    74  |   106 
  No               |  30.2  |  69.8  |  61.6 
                   |  51.6  |  67.3  | 
                   +--------+--------+ 
            Column      62      110      172 
             Total    36.0     64.0    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                          4.11185           1                  .04258 
Continuity Correction            3.47630           1                  .06225 
Likelihood Ratio                 4.07818           1                  .04344 
Mantel-Haenszel test for         4.08794           1                  .04319 
      linear association 
 
Minimum Expected Frequency -   23.791 
 
 
 
Number of Missing Observations:  0 
 
 
PC7  by  TREAT  Treatment 
 
                    TREAT        Page 1 of 1 
            Count  | 
           Row Pct |Curative Paliativ 
           Col Pct |         e          Row 
                   |       1|       2| Total 
PC7        --------+--------+--------+ 
                1  |     6  |    13  |    19 
  Yes              |  31.6  |  68.4  |  11.0 
                   |   9.7  |  11.8  | 
                   +--------+--------+ 
                2  |    56  |    97  |   153 
 
  No               |  36.6  |  63.4  |  89.0 
                   |  90.3  |  88.2  | 
                   +--------+--------+ 
            Column      62      110      172 
             Total    36.0     64.0    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                           .18493           1                  .66717 
Continuity Correction             .03123           1                  .85972 
Likelihood Ratio                  .18819           1                  .66443 
Mantel-Haenszel test for          .18385           1                  .66808 
      linear association 
 
Minimum Expected Frequency -    6.849 
 
 
 
Number of Missing Observations:  0 
 
 
PC8  by  TREAT  Treatment 
 
                    TREAT        Page 1 of 1 
            Count  | 
           Row Pct |Curative Paliativ 
           Col Pct |         e          Row 
                   |       1|       2| Total 
PC8        --------+--------+--------+ 
                1  |    22  |     9  |    31 
  Yes              |  71.0  |  29.0  |  18.0 
                   |  35.5  |   8.2  | 
                   +--------+--------+ 
                2  |    40  |   101  |   141 
  No               |  28.4  |  71.6  |  82.0 
                   |  64.5  |  91.8  | 
                   +--------+--------+ 
            Column      62      110      172 
             Total    36.0     64.0    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                         20.00427           1                  .00001 
Continuity Correction           18.19907           1                  .00002 
Likelihood Ratio                19.33087           1                  .00001 
Mantel-Haenszel test for        19.88796           1                  .00001 
      linear association 
 
Minimum Expected Frequency -   11.174 
 
 
 
Number of Missing Observations:  0 
 
 
PC9  by  TREAT  Treatment 
 
                    TREAT        Page 1 of 1 
            Count  | 
           Row Pct |Curative Paliativ 
           Col Pct |         e          Row 
                   |       1|       2| Total 
PC9        --------+--------+--------+ 
                1  |     2  |    13  |    15 
  Yes              |  13.3  |  86.7  |   8.7 
                   |   3.2  |  11.8  | 
                   +--------+--------+ 
                2  |    60  |    97  |   157 
  No               |  38.2  |  61.8  |  91.3 
                   |  96.8  |  88.2  | 
                   +--------+--------+ 
            Column      62      110      172 
             Total    36.0     64.0    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                          3.67746           1                  .05515 
Continuity Correction            2.67728           1                  .10179 
Likelihood Ratio                 4.24162           1                  .03944 
Mantel-Haenszel test for         3.65608           1                  .05587 
      linear association 
 
Minimum Expected Frequency -    5.407 
 
 
 
Number of Missing Observations:  0 
 
 
PC10  by  TREAT  Treatment 
 
                    TREAT        Page 1 of 1 
            Count  | 
           Row Pct |Curative Paliativ 
           Col Pct |         e          Row 
                   |       1|       2| Total 
PC10       --------+--------+--------+ 
                1  |     5  |    17  |    22 
  Yes              |  22.7  |  77.3  |  12.8 
                   |   8.1  |  15.5  | 
                   +--------+--------+ 
                2  |    57  |    93  |   150 
  No               |  38.0  |  62.0  |  87.2 
                   |  91.9  |  84.5  | 
                   +--------+--------+ 
            Column      62      110      172 
             Total    36.0     64.0    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                          1.94129           1                  .16353 
Continuity Correction            1.33531           1                  .24786 
Likelihood Ratio                 2.06628           1                  .15059 
Mantel-Haenszel test for         1.93001           1                  .16476 
      linear association 
 
Minimum Expected Frequency -    7.930 
 
 
 
Number of Missing Observations:  0 
 
 
PC11  by  TREAT  Treatment 
 
                    TREAT        Page 1 of 1 
            Count  | 
           Row Pct |Curative Paliativ 
           Col Pct |         e          Row 
                   |       1|       2| Total 
PC11       --------+--------+--------+ 
                1  |     1  |        |     1 
  Yes              | 100.0  |        |    .6 
                   |   1.6  |        | 
                   +--------+--------+ 
                2  |    61  |   110  |   171 
  No               |  35.7  |  64.3  |  99.4 
                   |  98.4  | 100.0  | 
                   +--------+--------+ 
            Column      62      110      172 
             Total    36.0     64.0    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                          1.78457           1                  .18159 
Continuity Correction             .08495           1                  .77070 
Likelihood Ratio                 2.05111           1                  .15209 
Mantel-Haenszel test for         1.77419           1                  .18286 
      linear association 
Fisher's Exact Test: 
   One-Tail                                                           .36047 
   Two-Tail                                                           .36047 
 
Minimum Expected Frequency -     .360 
Cells with Expected Frequency < 5 -     2 OF     4 ( 50.0%) 
 
 
 
Number of Missing Observations:  0 
 
 
PC12  by  TREAT  Treatment 
 
                    TREAT        Page 1 of 1 
            Count  | 
           Row Pct |Curative Paliativ 
           Col Pct |         e          Row 
                   |       1|       2| Total 
PC12       --------+--------+--------+ 
                1  |     5  |     8  |    13 
  Yes              |  38.5  |  61.5  |   7.6 
                   |   8.1  |   7.3  | 
                   +--------+--------+ 
                2  |    57  |   102  |   159 
  No               |  35.8  |  64.2  |  92.4 
                   |  91.9  |  92.7  | 
                   +--------+--------+ 
            Column      62      110      172 
             Total    36.0     64.0    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                           .03558           1                  .85039 
       
 
       
 
VOGD  VOGD  by  TREAT  Treatment 
Controlling for.. 
PC8  Value = 1  Yes 
 
                    TREAT        Page 1 of 1 
            Count  | 
           Row Pct |Curative Paliativ 
           Col Pct |         e          Row 
                   |       1|       2| Total 
VOGD       --------+--------+--------+ 
                1  |    20  |     3  |    23 
  Antral growth    |  87.0  |  13.0  |  74.2 
                   |  90.9  |  33.3  | 
                   +--------+--------+ 
 
                2  |     2  |     1  |     3 
  Mid Body growth  |  66.7  |  33.3  |   9.7 
                   |   9.1  |  11.1  | 
                   +--------+--------+ 
                3  |        |     2  |     2 
  OG Junction grow |        | 100.0  |   6.5 
                   |        |  22.2  | 
                   +--------+--------+ 
                4  |        |     3  |     3 
  Diffuse gastric  |        | 100.0  |   9.7 
                   |        |  33.3  | 
                   +--------+--------+ 
            Column      22        9       31 
             Total    71.0     29.0    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                         15.10291           3                  .00173 
       
 
GOO  by  TREAT  Treatment 
 
                    TREAT        Page 1 of 1 
            Count  | 
           Row Pct |Curative Paliativ 
           Col Pct |         e          Row 
                   |       1|       2| Total 
GOO        --------+--------+--------+ 
                1  |    24  |    32  |    56 
  Yes              |  42.9  |  57.1  |  58.3 
                   |  52.2  |  64.0  | 
                   +--------+--------+ 
                2  |    22  |    18  |    40 
  No               |  55.0  |  45.0  |  41.7 
                   |  47.8  |  36.0  | 
                   +--------+--------+ 
            Column      46       50       96 
             Total    47.9     52.1    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                          1.37858           1                  .24034 
       
 
- - - - - Chi-Square Test 
 
     AGE_G     Age Group 
 
                                     Cases 
                        Category  Observed  Expected  Residual 
 
     Below 40                  1        24     43.00    -19.00 
     41-50                     2        39     43.00     -4.00 
     51-60                     3        44     43.00      1.00 
     Above 60                  4        65     43.00     22.00 
                                       --- 
                           Total       172 
 
          Chi-Square            D.F.         Significance 
            20.0465               3              .0002 
 
 
       
 
VOGD  VOGD  by  TREAT  Treatment 
Controlling for.. 
PC10  Value = 1  Yes 
 
                    TREAT        Page 1 of 1 
            Count  | 
           Row Pct |Curative Paliativ 
           Col Pct |         e          Row 
                   |       1|       2| Total 
VOGD       --------+--------+--------+ 
                1  |     1  |     1  |     2 
  Antral growth    |  50.0  |  50.0  |   9.1 
                   |  20.0  |   5.9  | 
                   +--------+--------+ 
                2  |     1  |     1  |     2 
  Mid Body growth  |  50.0  |  50.0  |   9.1 
                   |  20.0  |   5.9  | 
                   +--------+--------+ 
                3  |     3  |    13  |    16 
  OG Junction grow |  18.8  |  81.3  |  72.7 
                   |  60.0  |  76.5  | 
                   +--------+--------+ 
                4  |        |     2  |     2 
  Diffuse gastric  |        | 100.0  |   9.1 
                   |        |  11.8  | 
                   +--------+--------+ 
            Column       5       17       22 
             Total    22.7     77.3    100.0 
 
      Chi-Square                  Value           DF               Significance 
--------------------          -----------        ----              ------------ 
 
Pearson                          2.42647           3                  .48873 
